

## خلاصه رزومه



### دکتر داود بیکی

#### تحصیلات

- متولد سال ۱۳۴۹ تهران
- اخذ مدرک دیپلم علوم تجربی از دبیرستان سرگرد رئیسی یزد - سال ۱۳۶۸
- اخذ مدرک دکتری عمومی داروسازی از دانشگاه علوم پزشکی تهران - سال ۱۳۷۴
- اخذ مدرک دکتری تخصصی (PhD) داروسازی هسته ای از دانشگاه علوم پزشکی تهران - سال ۱۳۷۹
- دوره Radiation Safety از دانشگاه آلبرتا کانادا - سال ۱۹۹۹
- دوره Post-doc رادیوفارمسی/ رادیوشیمی از دانشگاه آلبرتا کانادا - سال ۲۰۰۰
- دوره GMP و QC از کمپانی Eczacıbaşı / Monrol - ۲۰۱۲

#### تجارب آموزشی، پژوهشی و اجرایی

- استادیار دانشکده پزشکی دانشگاه علوم پزشکی تهران از سال ۱۳۸۰
- دانشیار دانشکده پزشکی دانشگاه علوم پزشکی تهران از سال ۱۳۸۵
- استاد دانشکده پزشکی دانشگاه علوم پزشکی تهران از سال ۱۳۹۰
- تا سپتامبر ۲۰۲۴ : نگارش ۱۸۵ مقاله در مجلات معتبر بین المللی، انجام ۷۱ طرح پژوهشی بعنوان مجری و همکار، ارائه ۲۲۶ مقاله در کنگره های ملی و بین المللی، راهنمایی و مشاوره ۸۰ پایان نامه در مقاطع مختلف تحصیلی
- نایب رئیس انجمن عملی داروسازی هسته ای ایران از ۱۴۰۲
- رئیس مرکز تحقیقات پزشکی هسته ای دانشگاه علوم پزشکی تهران از سال ۱۴۰۱ تاکنون
- عضو هیات مدیره انجمن علمی پزشکی هسته ای ایران از ۱۳۸۷ تا ۱۳۹۰ و از ۱۴۰۰ تاکنون
- عضو قطب علمی رادیوداروها از ۱۳۹۱ تاکنون
- عضو هیئت ممکنه و ارزشیابی رشته تخصصی داروسازی هسته ای با حکم وزیر محترم بهداشت، درمان و آموزش پزشکی از سال ۱۳۸۱ تاکنون
- دبیر هیئت ممکنه و ارزشیابی رشته تخصصی داروسازی هسته ای با حکم وزیر محترم بهداشت، درمان و آموزش پزشکی از سال ۱۳۹۵ تاکنون
- عضو هیئت ممکنه ارتقاء، گواهینامه و دانشنامه رشته تخصصی پزشکی هسته ای با حکم وزیر محترم بهداشت، درمان و آموزش پزشکی از سال ۱۳۸۵ تاکنون
- جانشین دبیر هیات بود تخصصی پزشکی هسته ای با حکم وزیر محترم بهداشت، درمان و آموزش پزشکی از سال ۱۳۸۹ تا ۱۴۰۰

- عضو هیئت ممتحنه و ارزشیابی منطقه ای رشته شیمی دارویی از سال ۱۳۹۷
- عضو شورای پژوهشی دانشگاه علوم پزشکی تهران از سال ۱۳۸۴ تاکنون
- عضو هیات موسس و عضو شورایی مرکز تحقیقات پزشکی هسته ای دانشگاه علوم پزشکی تهران
- عضو هیات موسس و شورایی قطب آموزشی پزشکی هسته ای
- معاون پژوهشی گروه پزشکی هسته ای دانشکده پزشکی دانشگاه ع پ تهران از سال ۱۳۸۲ تا ۱۳۹۸
- عضو شورای پژوهشی دانشکده پزشکی دانشگاه علوم پزشکی تهران از سال ۱۳۸۲ تا ۱۳۹۸
- معاون پژوهشی مرکز تحقیقات پزشکی هسته ای دانشگاه علوم پزشکی تهران از سال ۱۳۸۴ تا ۱۴۰۱
- کارشناس و نماینده اداره کل دارو و مواد مخدر وزارت بهداشت در امور رادیودارو ها- ۱۳۸۲
- عضو گروه آموزشی داروسازی هسته ای دانشکده داروسازی دانشگاه علوم پزشکی تهران با حفظ وظایف آموزشی، پژوهشی و درمانی در دانشکده پزشکی از ۱۳۸۷
- عضو شبکه تحقیقات سرطان از ۱۳۸۵ تاکنون
- کارشناس و مشاور شورای بررسی و تدوین رادیودارو های ایران- ۱۳۸۸
- کارشناس و مشاور آزمایشگاههای کنترل غذا و دارو- ۱۳۸۹
- عضو کمیته ارزشیابی دانشکده های داروسازی در شورای آموزش داروسازی و تخصصی - ۱۳۸۷
- عضو کمیته ارزشیابی بخش های آموزش تخصصی پزشکی هسته ای دانشگاههای علوم پزشکی کشور از ۱۳۸۶
- عضو کمیته تدوین برنامه آموزشی رشته تکنولوژی پزشکی هسته ای- ۱۳۸۶
- عضو کمیته تدوین برنامه آموزشی (کوریکولوم) رشته تخصصی پزشکی هسته ای- ۱۳۸۵
- عضو کمیته تدوین برنامه آموزشی رشته تخصصی داروسازی هسته ای- ۱۳۸۵
- عضو "کمیته دارو" بیمارستان دکتر شریعتی از سال ۱۳۸۷
- عضو "کمیته جذب گروه آموزشی پزشکی هسته ای دانشگاه ع پ تهران" از سال ۱۳۸۸
- عضو "کمیته اجرایی طرح ملی رادیودارو ها" از سال ۱۳۸۹
- عضو "کمیته تدوین فارماکوپه ایران" از سال ۱۳۹۶
- معاون سردبیر و مدیر اجرایی مجله Iranian Journal of Nuclear Medicine از سال ۲۰۰۱ تا ۲۰۱۹
- سردبیر مجله Iranian Journal of Nuclear Medicine از سال ۲۰۲۰
- عضو کمیته علمی و اجرایی کنگره های سالیانه پزشکی هسته ای ایران از سال ۱۳۸۲ تاکنون (۱۷ کنگره)
- عضو کمیته اجرایی دوره آموزشی آسیایی کاردیولوژی هسته ای آژانس بین المللی انرژی اتمی- ۱۳۸۹
- عضو کمیته علمی و اجرایی و مسئول کمیته علمی Radiochemistry & Radiopharmacy دهمین کنگره آسیا و اقیانوسیه پزشکی هسته ای و بیولوژی- ۲۰۱۰
- عضو انجمن پزشکی هسته ای ایران از سال ۱۳۸۰
- عضو انجمن پزشکی هسته ای اروپا از سال ۲۰۰۵
- عضو هیات تحریریه در ۶ ژورنال و داوری مقالات دهها ژورنال معتبر علمی - تخصصی ملی و بین المللی

#### افتخارات و جوایز

- برگزیده نهمین جشنواره کشوری علوم پزشکی رازی - ۱۳۸۲
- برگزیده پنجمین جشنواره علوم پزشکی ابن سینا - ۱۳۸۲
- جایزه انجمن رینولوژی آمریکا - ۲۰۰۵

**آدرس:** تهران، خیابان کارگر شمالی، بیمارستان شریعتی، مرکز تحقیقات پزشکی هسته ای دانشگاه علوم پزشکی تهران

ایمیل: beikidav@sina.tums.ac.ir

فاکس: ۸۸۰۲۶۹۰۵

تلفن: ۸۸۶۳۳۳۳۳

## Curriculum Vitae

### **Davood Beiki, Pharm D, PhD**

Professor of Nuclear Pharmacy,  
Chairman, "Research Center for Nuclear Medicine",  
Tehran University of Medical Sciences, Shariati Hospital,  
North Kargar Ave. 1411713135, Tehran, Iran

Tel: ++98-21-88220361

Fax: ++98-21-88026905

E-mail: beikidav@sina.tums.ac.ir



### **BIOGRAPHY**

Dr. Davood Beiki acquired a PharmD in 1995 from the Tehran University of Medical Sciences (TUMS) and then finished a PhD in Radiopharmacy in 1999 from TUMS. He gained a postdoctoral training in Radiochemistry/Radiopharmacy at the University of Alberta in 2000. Dr. Beiki has obtained the honor of full professorship of Tehran University of Medical Sciences since 2012.

Dr. Beiki has been the Deputy for Research, Department of Nuclear Medicine of TUMS since 2005 and involved in Research Center for Nuclear Medicine of TUMS as a Co-Founder and Vice-Chair since 2006. He also has been Vice-Director of National Board of Nuclear Medicine since 2007, a member of National Board of Radiopharmacy since 2003, a member of TUMS Advisory Council for Research since 2006, Vice-Chair of National Center of Excellence in Nuclear Medicine since 2008, a member of National Center of Excellence in Radiopharmaceuticals since 2013, Director of National Board of Radiopharmacy since 2017, Vice-president of Iranian Association of Nuclear Pharmacy since 2023 and chairman in Research Center for Nuclear Medicine of TUMS since 2023.

So far, Dr. Beiki has contributed in authoring more than 185 scientific papers in prestigious journals and authoring three book chapters. Besides having the position of Iranian Journal of Nuclear Medicine Editor-in-Chief, a journal of published by TUMS, Dr. Beiki has also served on the editorial board of 12 other journals and is a member of many academic societies. He also has cooperated with some key organizations such as Iranian Cancer Research Network. The main research interests of Dr. Beiki are Radiopharmaceutical Chemistry and Hospital/Clinical Radiopharmacy.

## **EDUCATION**

### **Postdoctoral fellowship**

Radiochemistry/Radiopharmacy, University of Alberta, Edmonton, Canada, 1999-2000.  
Thesis Title: Part 1- Synthesis of 1-b-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (b-IAZA): a novel marker of tissue hypoxia, Part 2-Synthesis of b-azomycin nucleosides: 1-(b-D-2-iodo-2-deoxyarabinofuranosyl)-2-nitroimidazole, a novel marker of tissue hypoxia  
Supervisor: Professor Leonard Wiebe

### **Ph.D**

Nuclear Pharmacy, TUMS/University of Alberta (Sandwich Program), Tehran/Edmonton, Iran/Canada, 1995-1999.

Thesis Title: Tumor Imaging Agents: 1-Synthesis of tissue hypoxia Markers, 2- Radioiodination of antibodies

### **Pharm D**

Doctor of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran, 1989-1995  
Thesis Title: Comparative bioavailability of two tablet formulations of dipyridamole in healthy male volunteers

## **AWARDS & HONORS**

1. Razi Award for the foundations advocating medical sciences researches, Razi International Festival of Medical Sciences in Research, Tehran, Iran, 2005.
2. ARS Maurice H. Cottle Award, 51st Annual Meeting of the American Rhinologic Society, Los Angeles, California, USA, 2005.
3. Avicenna Award (Tehran University of Medical Sciences) for the young researcher, Tehran, Iran, 2003.
4. Razi Award for the young researcher in basic sciences, Razi International Festival of Medical Sciences in Research, Tehran, Iran, 2003.

## **SCIENTIFIC POSITION**

### **Professor of Nuclear Pharmacy**

Research Institute for Nuclear Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Since 2012.

### **Associate Professor of Nuclear Pharmacy**

Research Institute for Nuclear Medicine, Faculty of Medicine, Tehran University of Medical Sciences, 2006-2011.

### **Assistant Professor of Nuclear Pharmacy**

Research Institute for Nuclear Medicine, Faculty of Medicine, Tehran University of Medical Sciences, 2000-2005.

## EXECUTIVE POSITION

### Deputy for Research

Department of Nuclear Medicine, Faculty of Medicine, Tehran University of Medical Sciences, 2001-2019.

### Co-Founder and Deputy President

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, 2001-up to 2022.

### Director of National Board of Radiopharmacy

Ministry of Health and Medical Education, 2017-up to now.

### Chairman

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, 2022-up to now.

### Vise President

Iranian Association of Nuclear Pharmacy, 2023-up to now.

### Editor-in-Chief

Iranian Journal of Nuclear Medicine, 2020-up to now.

## BOOKS

1. **Beiki D**. Quality Control of Radiopharmaceuticals. In: **Textbook of Nuclear Pharmacy**. 2007; 195-235
2. Jokar S, Khazaei S, Gameshgoli XE, Khafaji M, Yarani B, Sharifzadeh M, **Beiki D**, Bavi O. Amyloid  $\beta$ -Targeted Inhibitory Peptides for Alzheimer's Disease: Current State and Future Perspectives. In: **Alzheimer's disease: Drug discovery**. Exon Publications: 2020; 51-68.
3. Jokar S, Khazaei S, Behnammanesh H, Laranjo M, **Beiki D**, Botelho MF. X-ray-based cancer diagnosis and treatment methods. In: **Electromagnetic waves-based cancer diagnosis and therapy**. Elsevier Inc. 2023; 239-94.

## PAPERS IN JOURNALS

1. **Beiki D**, Pirali M, Amini M, Shafiee A. High performance liquid chromatographic method for determination of dipyrindamole in human plasma. *DARU* **1999**;7(2):14-17.
2. Khalaj A, **Beiki D**, Rafiee H, Najafi R. A new and simple synthesis of N-succinimidyl-4- $^{125}\text{I}$ iodobenzoate involving a microwave-accelerated iodination step. *J Label Compd Radiopharm* **2001**;44(3):235-240.
3. **Beiki D**, Shahhosseini S, Khalaj A, Eftekhari M. Increased selectivity in inflammatory site identification via labelling of IgG with N-succinimidyl-4- $^{125}\text{I}$ iodobenzoate. *J Label Compd Radiopharm* **2002**;45(11):927-34.
4. Kumar P, Wiebe LI, **Beiki D**, Ohkura K, Seki KI. Synthesis of b-azomycin nucleosides: 1-(b-D-2-iodo-2-deoxyarabinofuranosyl)-2-nitroimidazole, a novel marker of tissue hypoxia. *Tetrahedron Lett* **2002**;43:4427-4429.

5. Kumar P, Ohkura K, **Beiki D**, Wiebe LI, Seki KI. Synthesis of 1-b-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (b-IAZA): a novel marker of tissue hypoxia. *Chem Pharm Bull* **2003**;51(4): 399-403.
6. Matloobi M, Rafii H, **Beiki D**, Khalaj A, Kamali-Dehghan M. Synthesis of radioiodinated labeled peptides. *J Radioanal Nucl Chem* **2003**;257(1):71-73.
7. **Beiki D**, Shahhosseini S, Eftekhari M, Takavar A. Contamination monitoring of Na <sup>131</sup>I level in therapy unit of Research Institute for Nuclear Medicine, Tehran University of Medical Sciences, by indirect method (wipe test). *Iran J Nucl Med* **2003**;11(1):9-16.
8. **Beiki D**, Amini M, Dowlatabadi R, Pirali M. Comparative bioavailability of two tablet formulation of dipyrindamole in healthy male volunteers. *Iran J Pharm Res* **2003**;2:213-216.
9. Fard-Esfahani A, Olamaei R, Eftekhari M, Saghari M, **Beiki D**. Radioiodine therapy effects on salivary gland function in patients with differentiated thyroid cancer. *Iran J Nucl Med* **2003**;11(1):17-21.
10. Shahhosseini S, **Beiki D**, Eftekhari M. Gamma-scintigraphy in the evaluation of drug delivery systems. *Iran J Nucl Med* **2003**;11(2):21-33.
11. Eftekhari M, Olamaei R, Fard A, **Beiki D**, Saghari M. <sup>131</sup>I-MIBG scintigraphy in carcinoid tumor with liver metastases. *Iran J Nucl Med* **2003**;11(2):7-11.
12. Eftekhari M, Takavar A, Ansari-Gilani K, Akhzari F, Fard A, **Beiki D**. Effects of treatment with radioiodine (<sup>131</sup>I) on the gonadal function of the hyperthyroid patients. *Iran J Nucl Med* **2003**;11(2):7-12.
13. Takavar A, Eftekhari M, **Beiki D**, Saghari M, Mostaghim M, Sohrabi M. Qualitative evaluation of Chang method of attenuation correction on heart SPECT by using custom made heart phantom. *Iran J Nucl Med* **2003**;11(2):13-17.
14. **Beiki D**, Shahhosseini S, Dadashzadeh S, Eftekhari M, Tayebi H, Moosazadeh-Rashti G. Determination of radiation dose rates and urinary activity of patients received sodium iodide-131 for treatment of differentiated thyroid carcinoma. *Iran J Nucl Med* **2004**;12(1):1-13.
15. Saghari M, Fallahi B, Eftekhari M, Iravani M, Izadyar S, Esmaili J, **Beiki D**, Fard A. Value of <sup>99m</sup>Tc-MIBI scintigraphy in active disease and remission phase of multiple myeloma. *Iran J Nucl Med* **2004**;21(1):15-23.
16. Eftekhari M, Sadeghi R, Fard A, **Beiki D**, Fallahi B, Saghari M. Reverse re-distribution in myocardial perfusion scan with <sup>201</sup>Tl. *Iran J Nucl Med* **2004**;12(1):25-32.
17. Eftekhari M, Assadi M, Fard-Esfahani A, **Beiki D**, Fallahi B. Dystrophic calcinosis cutis and SLE; the bone scan pattern (Case report). *Iran J Nucl Med* **2004**;12(2):1-4.
18. Fard-Esfahani A, Eftekhari M, Aliyari N, Saghari M, **Beiki D**. Effects of treatment with radioactive iodine on gonadal functions in patients with differentiated thyroid cancer. *Tehran Uni Med J (TUMJ)* **2004**;62(1):31-36.
19. Fard A, Emami F, Eftekhari M, Saghari M, Fallahi B, **Beiki D**, Takavar A. The value of myocardial perfusion imaging in differentiating between idiopathic dilated cardiomyopathy from the ischemic form. *Iran J Nucl Med* **2004**;12(2):15-20.

20. Shahhosseini S, **Beiki D**, Dadashzadeh S, Eftekhari M, Tayebi H, Moosazadeh G. Radiation dose rate and urinary activity in patients with differentiated thyroid carcinoma treated with radioiodine-131; a survey in Iranian population. *Hell J Nucl Med* **2004**;7(3):192-194.
21. Fard A, Fallahi B, Olamaei R, Eftekhari M, **Beiki D**, Saghari M. Semi-quantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment. *Hell J Nucl Med* **2004**;7(3):206-209.
22. Dowlatabadi R, Khalaj A, **Beiki D**, Eftekhari M, Al-Seyed Hosein MH, Khoshayand MR. Microdose <sup>14</sup>C Urea breath test for the diagnosis of Helicobacter Pylori: a survey in Iranian population. *DARU* **2005**;13(1):6-10.
23. **Beiki D**, Khalaj A, Dowlatabadi R, Eftekhari M, Al-Seyed Hosein MH, Fard A, Fallahi B, Khoshayand MR. Validation of <sup>13</sup>C-urea breath test with non dispersive isotope selective infrared spectroscopy for the diagnosis of Helicobacter pylori infection: a survey in Iranian population. *DARU* **2005**;13(2):52-55.
24. Dowlatabadi R, **Beiki D**, Khalaj A. Radiopharmaceutical regulation world wide - the resemblances and the differences. *Iran J Nucl Med* **2005**;13(1):1-13.
25. Saghari M, Moslehi M, Esmaeili J, Tahmasebi MN, Radmehr A, Eftekhari M, Fard-Esfahani A, **Beiki D**, Fallahi B, Gholamrezanezhad A. Accuracy of SPECT bone scintigraphy in diagnosis of meniscal tears. *Iran J Nucl Med* **2005**;13(1):1-6.
26. Beiki O, **Beiki D**. Parsmedline: establishment of a web-based bibliographic database related to Iranian health and medical research. *J Med Libr Assoc* **2005**;93(3):400-403.
27. Avadi MR, Ghassemi AH, Sadeghi AMM, **Beiki D**, Akbarzadeh A, Ebrahimnejad P, Shahhosseini S, Bayati KH, Rafiiee-Tehrani M. Gammascintigraphy evaluation of enteric-coated capsules containing chitosan-brilliant blue gel beads as hydrophilic model for colon drug delivery. *J Drug Del Sci Technol* **2005**;15(5):383-387.
28. Fard A, Dabbagh VR, Fallahi B, Eftekhari M, **Beiki D**, Saghari M, Takavar A. Comparative evaluation of two fixed doses of 185 and 370 MBq <sup>131</sup>I, for the treatment of Graves' disease resistant to antithyroid drugs. *Hell J Nucl Med* **2005**;8(3):165-168.
29. Fallahi B, Saghari M, Fard A, Eftekhari M, Irvani M, **Beiki D**, Dabbagh VR, Sadeghi R. The value of <sup>99m</sup>Tc-MIBI whole body scintigraphy in active and in remission multiple myeloma. *Hell J Nucl Med* **2005**;8(3):158-161.
30. Gholamrezanezhad A, Eftekhari M, Fard A, Fallahi B, **Beiki D**. Unilateral absent lung ventilation and perfusion due to hilar mass. *Hell J Nucl Med* **2005**;8(3):169-170.
31. Fard Esfahani A, Akhzari F, Mirshekarpour H, Saghari M, Izadyar S, Esmaili J, Fallahi B, **Beiki D**. Radioiodine treatment effects on lacrimal glands function in patients with thyroid cancer. *Iran J Nucl Med* **2005**;13(2):6-14.
32. Eftekhari M, Saghari M, Noorani MH, Fard-Esfahani A, **Beiki D**, Fallahi B. Evaluation of diagnostic role of <sup>99m</sup>Tc-Tetrofosmin scintigraphy in cold thyroid nodules. *Iran J Nucl Med* **2005**;13(2):25-29.
33. Eftekhari M, Assadi M, Kazemi M, Saghari M, Fard-Esfahani A, Fallahi Sichani B, Gholamrezanezhad A, **Beiki D**. A preliminary study of neuroSPECT evaluation of patients with posttraumatic smell impairment. *BMC Nuclear Medicine* **2005**;5(6):doi;10.1186-1471-2385-5-6.

34. Fard-Esfahani A, Assadi M, Saghari M, Eftekhari M, Fallahi Sichani B, **Beiki D**, Akbarpour S, Mohammadian B. Myocardial <sup>99m</sup>Tc-MDP uptake on the bone scintigraphy in the hemodialysis-associated amyloidosis: A case report. *Iran J Nucl Med* **2005**;13(2):1-5.
35. Saghari M, Assadi M, Eftekhari M, Yaghoubi M, Fard-Esfahani A, Malekzadeh J, Fallahi B, **Beiki D**, Takavar A. Frequency and severity of myocardial perfusion abnormalities using Tc-99m-MIBI SPECT in cardiac syndrome X. *BMC Nucl Med* **2006**;6(1):doi;10.1186/1471-2385-6-1.
36. Saghari M, Gholamrezanezhad A, Mirpour S, Eftekhari M, Takavar A, Fard-Esfahani A, Fallahi B, **Beiki D**. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. *Nucl Med Commun* **2006**;27(7):567-72.
37. Fallahi B, **Beiki D**, Assadi M, Fard-Esfahani A. Thallium-201 single photon emission tomography after injecting an antimuscarinic agent compared with computed tomography for the diagnosis of recurrent colorectal cancer: Report of three cases. *Hell J Nucl Med* **2006**;9(2):106-108.
38. Eftekhari M, Gholamrezanezhad A, Izadyar S, Esmaili J, Mirpour S, Saghari M, Fard-Esfahani A, Fallahi Sichani B, **Beiki D**. Catheter related artifacts on bone scans: report of two cases. *Iran J Nucl Med* **2006**;14(1):21-25.
39. Eftekhari M, Assadi M, Kazemi M, Saghari M, Mojtahedi A, Fard-Esfahani A, Sichani BF, **Beiki D**. Brain perfusion single photon emission computed tomography findings in patients with posttraumatic anosmia and comparison with radiological imaging. *Am J Rhinol* **2006**;20(6):577-81.
40. Fard-Esfahani A, Fallahi B, Khatami K, Eftekhari M, Saghari M, **Beiki D**, Ansari-Gilani K, Takavar A. Agreement of two methods of planar and SPECT scintigraphy with <sup>99m</sup>Tc-RBC in detection of liver hemangioma. *Iran J Nucl Med* **2006**;14(2):8-12.
41. Fard-Esfahani A, Nazar-Ahari M, Assadi M, Saghari M, Eftekhari M, Fallahi B, **Beiki D**, Takavar A. Role of Tc-99m RBC scintigraphy in specific diagnosis of liver hemangioma. *Alasbimn J* **2006**;8(32):32-37.
42. Fard-Esfahani A, Haddad P, Modares Mosalla MM, Fallahi B, Eftekhari M, Saghari M, **Beiki D**, Takavar A. Efficacy of pilocarpine for the prevention of radiation induced xerostomia evaluated by semi-quantitative <sup>99m</sup>Tc-pertechnetate scanning in a randomized trial. *Cancer Bulletin* **2006**;2:65-76.
43. Gholamrezanezhad A, Mirpour S, Esfahani AF, Saghari M, Mirpour K, **Beiki D**, Soheilifar M. A correlative study comparing current different methods of calculating left ventricular ejection fraction. *Nucl Med Commun* **2007**;28(1):41-48.
44. Gholamrezanezhad A, Saghari M, Mirpour S, **Beiki D**, Javan S, Abdollahzadeh J. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma. *Pol J Endocrinol* **2007**;58(2):100-104.
45. **Beiki D**, Gholamrezanezhad A, Mirpour S, Fallahi B, Saghari M, Eftekhari M, Fard-Esfahani A, Hajimahmoudi H. The relationship between dyspepsia and increased radiotracer uptake in the gastric wall during <sup>99m</sup>Tc-MIBI myocardial perfusion imaging. *J Mazandaran Univ Med Sci* **2007**;16(56):1-8.

46. Fard-Esfahani A, Fallahi B, Saghari M, Eftekhari M, **Beiki D**. Myocardial Perfusion Scan Accuracy in Detection of Coronary Artery Disease - Comparison with Exercise Stress Test. *Iran J Nucl Med* **2007**;15(1):16-23.
47. Fard-Esfahani A, Mirshekarpour H, Fallahi B, Eftekhari M, Saghari M, **Beiki D**, Ansari-Gilani K, Takavar A. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. *Clin Nucl Med* **2007**;32(9):696-699.
48. Gholamrezanezhad A, Fard-Esfahani A, Sadeghi-Tari A, Mirpour S, Saghari M, Eftekhari M, Fallahi B, **Beiki D**, Poormoslemi A, Tarbiat A. Quantitative assessment of dacryoscintigraphic images in the evaluation of epiphora. *Orbit* **2007**;26(4):229-235.
49. Gholamrezanezhad A, Bagheri M, Mohammadnezhad M, Mirpour S, Majd Ardekani J, Alimoghadam K, Bashtar M, **Beiki D**, Ansari Gilani K, Saghari M, Ghavamzadeh A, Malekzadeh R. The First Experience of Stem Cell Labeling in Iran Using <sup>111</sup>In- Oxine. *Iran J Nucl Med* **2007**;15(2):25-27.
50. **Beiki D**, Eftekhari M, Fallahi B, Gheisari F, Hozhabrosadati M, Fard-Esfahani A, Takavar A, Gholamrezanezhad A, Saghari M, Ansari Gilani K. Comparative scintigraphic study of renal function with <sup>99m</sup>Tc-Mercaptoacetyl-triglycine and <sup>99m</sup>Tc-Ethylenedicycysteine. *DARU* **2008**;16(1):41-46.
51. Fallahi B, **Beiki D**, Gholamrezanezhad A, Mahmoudian B, Ansari Gilani K, Eftekhari M, Fard-Esfahani A, Mohseni Z, Saghari M. Single Tc-99m Sestamibi injection, double acquisition gated SPECT after stress and during low-dose dobutamine infusion: a new suggested protocol for evaluation of myocardial perfusion. *Int J Cardiovasc Imaging* **2008**;24(8):825-835.
52. Pooyafard F, Fallahi B, Assadi SM, Amini H, **Beiki D**, Fard-Esfahani A, Rahiminezhad F, Shahmansouri N, Mohammadi MR. The pattern of brain perfusion SPECT in non-medicated schizophrenic patients. *Iran J Nucl Med* **2008**;16(1):43-51.
53. Eftekhari M, Asadollahi A, **Beiki D**, Izadyar S, Gholamrezanezhad A, Assadi M, Fard-Esfahani A, Fallahi B, Takavar A, Saghari M. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment. *Hell J Nucl Med* **2008**;11(3):160-163.
54. Fard-Esfahani A, Gholamrezanezhad A, Mirpour S, Tari AS, Saghari M, **Beiki D**, Sichani BF, Eftekhari M. Assessment of the accuracy of lacrimal scintigraphy based on a prospective analysis of patients' symptomatology. *Orbit* **2008**;27(4):237-241.
55. Fallahi B, Bostani M, Ansari Gilani K, **Beiki D**, Gholamrezanezhad A. Manifestations of Ollier's disease in a 21-years old man: a case report. *J Med Case Reports* **2009**;3:7759.
56. Hosseinimehr SJ, Ahmadi A, **Beiki D**, HabibiE, Mahmoudzadeh A. Protective effects of hesperidin against genotoxicity induced by <sup>99m</sup>Tc-MIBI in human cultured lymphocyte cells. *Nucl Med Biol* **2009**;36:863-867.
57. Hosseinimehr SJ, Ahmadi A, **Beiki D**, Mahmoudzadeh A, Babaei M, Habibi E. The radiotracer <sup>99m</sup>Tc-MIBI is not genotoxic for human peripheral blood lymphocytes. *Genet Mol Res* **2009**;8(3):923-928.
58. Fard-Esfahani A, Hadifar M, Fallahi B, **Beiki D**, Eftekhari M, Saghari M, Takavar A. Radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma. *Hell J Nucl Med* **2009**;12(1):37-40.

59. Fallahi B, **Beiki D**, Eftekhari M, Ansari Gilani K, Fard-Esfahani A, Gholamrezanezhad A, Yamini Sharif A, Ansari M, Saghari M. High accuracy of myocardial perfusion imaging in patients with left bundle branch block: comparison of four interpretation approaches. *Hell J Nucl Med* **2009**;12(2):132-137.
60. Eftekhari M, **Beiki D**, Fallahi B, Arabi M, Memari F, Gholamrezanezhad A, Esmaeili J, Akhzari F, Fard-Esfahani A. Assessment the diagnostic accuracy of sentinel lymph nodes lymphoscintigraphy using Technetium-99m phytate in breast cancer. *Daru* **2009**;17(2):83-87.
61. Fard-Esfahani A, Assadi M, Saghari M, Mohagheghie A, Fallahi B, Eftekhari M, **Beiki D**, Takavar A, Nabipour I, Ebrahimi A, Izadyar S, Ansari-Gilani K. The role of myocardial perfusion imaging in the evaluation of patients undergoing percutaneous transluminal coronary angioplasty. *Hell J Cardiol* **2009**;50(5):396-401.
62. Ansari Gilani K, Modaresi Esfeh J, Gholamrezanezhad A, Gholami A, Mamishi S, Eftekhari M, **Beiki D**, Fard-Esfahani A, Fallahi B, Anvari A. Predictors of abnormal renal cortical scintigraphy in children with first urinary tract infection: the importance of time factor. *Int Urol Nephrol* **2009**; 42(4):1041-1047.
63. Fard-Esfahani A, Chavoshi M, Eftekhari M, Fallahi B, **Beiki D**, Saghari M. Giant cavernous hemangioma on Tc-99m RBC scan. *Iran J Nucl Med* **2009**;17(1):57-60.
64. Fallahi B, **Beiki D**, Mousavi SA, Gholamrezanezhad A, Eftekhari M, Fard-Esfahani A, Alimoghadam K, Mirpour S, Skandarian A, Saghari M. <sup>99m</sup>Tc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance for the prediction of multiple drug resistance. *Hell J Nucl Med* **2009**;12(3):255-259.
65. Hosseinimehr SJ, **Beiki D**, Kebriaeezadeh A, Khalaj A, Pirali Hamedani M, Akhlaghpour S, Esmaeili H, Barazesh A. "Synthesis and radioprotective study of novel amino-alkyldithiocarbamic acid derivatives against  $\gamma$ -irradiation in mice. *Iran J Radiat Res* **2009**;7(2):91-96.
66. **Beiki D**, Fallahi B, Mohseni M, Khalaj A, Fard-Esfahani A, Eftekhari M. Initial and delayed stress phase imaging in a single-injection double-acquisition SPECT: The potential value of early <sup>99m</sup>Tc-MIBI redistribution in assessment of myocardial perfusion reversibility in patients with coronary artery disease. *Nuklearmedizin* **2010**;49(1):19-27.
67. Fard-Esfahani A, Fallahi B, Mohagheghi A, Assadi M, **Beiki D**, Eftekhari M, Saghari M, Takavar A. The value of myocardial perfusion imaging with Tc-99m MIBI for the prediction of perfusion improvement after percutaneous transluminal coronary angioplasty. *Iran J Nucl Med* **2010**;18(1):7-13.
68. Esfahani AF, Chavoshi M, Noorani MH, Saghari M, Eftekhari M, **Beiki D**, Fallahi B, Assadi M. Successful application of technetium-99m-labeled octreotide acetate scintigraphy in the detection of ectopic adrenocorticotropin-producing bronchial carcinoid lung tumor: a case report. *J Med Case Reports* **2010**;4:323.
69. Haghghatafshar M, Fard-Esfahani A, Karami F, Saghari M, Fallahi B, **Beiki D**, Aghahosseini F, Eftekhari M. McCune-Albright syndrome: Report of a case. *Iran J Nucl Med* **2010**;18(1):57-61.
70. Fallahi B, **Beiki D**, Fard-Esfahani A, Akbarpour S, Abolhassani A, Dabbagh Kakhki VR, Eftekhari M. The additive value of transient left ventricular dilation using two-day dipyridamole <sup>99m</sup>Tc-MIBI SPECT for screening coronary artery disease in patients with otherwise normal myocardial perfusion: a comparison between diabetic and non-diabetic cases. *Hell J Nucl Med* **2010**;13(3):246-252.

71. Fard-Esfahani A, **Beiki D**, Fallahi B, Mohajeri-Tehrani MR, Gharaie MR, Rouhipour N, Dehghanian M, Saghari M, Emami-Ardekani A, Eftekhari M. Evaluation of <sup>99m</sup>Tc-Ubiquicidin 29–41 scintigraphy in differentiation of bacterial infection from sterile inflammation in diabetic foot. *Iran J Nucl Med* **2010**;18(2):20-28.
72. Eftekhari M, Fard-Esfahani A, Haghghatafshar M, Keyvan A, **Beiki D**, Aghahosseini F, Emami-Ardekani A, Saghari M. Bone scan with incidental visualization of the entire colon. *Iran J Nucl Med* **2010**;18(2):56-59.
73. Mehrazin M, Nezameddini-Kachooei SA, Fallahi B, Derakhshan MK, **Beiki D**, Ghodsi SM, Assadi M, Pooyafard F, Eftekhari M. Prospective evaluation of technetium-99m ECD SPET in mild traumatic brain injury for the prediction of sustained neuropsychological sequels. *Hell J Nucl Med* **2011**;14(3):243-250.
74. Fallahi B, **Beiki D**, Khodaparast MB, Gholamrezanezhad A, Fard-Esfahani A, Eftekhari M. Additive clinical value of bone scintigraphy in patients with malignant tumors with absence of localized bone pain: A report on most common sex-related cancers. *Iran J Nucl Med* **2011**;19(1):52-58.
75. Ansari-Gilani K, Gholamrezanezhad A, **Beiki D**, Mirpour S, Modaresi Esfeh J. Renal axis deviation in urinary tract abnormalities of children: the role of renal scintigraphy. *Clin Nucl Med*. **2011**;36(12):1086-91.
76. Fallahi B, **Beiki D**, Takavar A, Fard-Esfahani A, Ansari Gilani K, Saghari M, Eftekhari M. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. *Nucl Med Commun* **2012**;33(3):275-282.
77. Fard-Esfahani P, Fallahi B, **Beiki D**, Fard-Esfahani A, Emami-Ardekani A, Eftekhari M, Ansari M. Molecular imaging with PET/CT in oncology. *Iran South Med J* **2012**;1:69-79.
78. Kalantari F, Rajabi H, Ay MR, Razavi-Ratki SK, Fard-Esfahani A, **Beiki D**, Eftekhari M, Fallahi B, Sadeghian L, Emami-Ardekani A. The influence of resolution recovery by using collimator detector response during 3D OSEM image reconstruction on <sup>99m</sup>Tc-ECD brain SPET images. *Hell J Nucl Med* **2012**;15(2):92-97.
79. Fard-Esfahani A, Farzanefar S, Fallahi B, **Beiki D**, Saghari M, Emami-Ardekani, Majdi M, Eftekhari M. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer. *Nucl Med Commun* **2012**;33(10):1077-80.
80. Fard-Esfahani A, Fallahi B, Mirpour S, Gholamrezanezhad A, Abdi E, Karimi M, **Beiki D**, Emami-Ardekani A, Akhzari F, Ansari M, Eftekhari M. Evaluation of myocardial perfusion and function after kidney transplantation by Gated SPECT myocardial perfusion scintigraphy. *Iran J Nucl Med*. **2012**;20(2):20-24.
81. Vahidfar N, Jalilian AR, Fazaeli Y, Bahrami-Samani A, **Beiki D**, Khalaj A. Development and evaluation of a 166holmium labelled porphyrin complex as a possible therapeutic agent. *J Radioanal Nucl Chem* **2013**;295:979-986.
82. Fallahi B, **Beiki D**, Akbarpour S, Gholamrezanezhad A, Fard-Esfahani A, Akhzari F, Izadyar S, Esmaeli J, Saghari M, Eftekhari M. Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial. *Daru*. **2013** Jan 15;21(1):8. doi: 10.1186/2008-2231-21-8.

83. Fallahi B, **Beiki D**, Abedi SM, Saghari M, Fard-Esfahani A, Akhzari F, Mokarami B, Eftekhari M. Does vitamin-E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? *Nucl Med Commun*. **2013**;34(8):777-786.
84. **Beiki D**, Yousefi G, Fallahi B, Tahmasebi MN, Gholamrezanezhad A, Fard-Esfahani A, Erfani M, Eftekhari M. <sup>99m</sup>Tc-Ubiquicidin [29–41], a promising radiopharmaceutical to differentiate orthopedic implant infections from sterile inflammation. *Iran J Pharm Res*. **2013**;12(2)347-353.
85. **Beiki D**, Haddad P, Fallahi B, Keyvan A, Gholamrezanezhad A, Mirzaei H, Saghari M, Amouzegar-Hashemi F, Kazemian A, Fard-Esfahani A, Eftekhari M. Effectiveness and complications of <sup>153</sup>Sm-EDTMP in palliative treatment of diffuse skeletal metastases. *Iran J Nucl Med*. **2013**;21(1)26-32.
86. Ahmadi F, Faizi M, Tabatabai SM, **Beiki D**, Shahhosseini S. Comparison [3H]-flumazenil binding parameters in rat cortical membrane using different separation methods, filtration and centrifugation. *Nucl Med Biol*. **2013**;40:896-900.
87. Aghanejad A, Jalilian AR, Fazaeli Y, **Beiki D**, Fateh B, Khalaj A. Radiosynthesis and biodistribution studies of [62Zn/62Cu]-Plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging. *J Radioanal Nucl Chem* **2014**;299:1635-1644.
88. Aghanejad A, Jalilian AR, Fazaeli Y, Alirezapoor B, Pouladi M, **Beiki D**. Synthesis and Evaluation of [67Ga]-AMD3100; a novel imaging agent for targeting chemokine receptor CXCR4. *Sci Pharm* **2014**; 299:1635-1644.
89. Emami-Ardekani A, Fallahi B, Amini M, Fard-Esfahani A, **Beiki D**, Farzanefar S, Abbasi M, Sadeghian L, Eftekhari M, Saghari M. Accuracy of modification of diet for renal disease and Cockcroft-Gault equations as compared to the radioisotope double sample method: A study in patients with acute renal failure. *Iran J Nucl Med* **2014**;22(1):23-28.
90. Zarrabi Ahrabi N, Erfani M, Parivar K, **Beiki D**, Jalilian AR. Preparation and evaluation of a new neurotensin analog labeled with 99mTc for targeted imaging of neurotensin receptor positive tumors. *J Radioanal Nucl Chem* **2014**;299:461-469.
91. Vahidfar N, Jalilian AR, Fazaeli Y, Aghanejad A, Bahrami-Samani A, Alirezapoor B, Erfani M, **Beiki D**, Khalaj A. Development of radiolanthanide labeled porphyrin complexes as possible therapeutic agents in breast carcinoma xenografts. *Radiochim Acta* **2014**;102(7):659-668.
92. Ahmadi F, Dabirian S, Faizi M, Tabatabai SM, **Beiki D**, Shahhosseini S. Optimum conditions of radioligand receptor binding assay of ligands of benzodiazepine receptors. *Iran J Pharm Res* **2014**;13:83-90.
93. Vahidfar N, Jalilian AR, Fazaeli Y, Bahrami-Samani A, **Beiki D**, Khalaj A. Radiosynthesis and biological evaluation of <sup>166</sup>Ho labeled methoxylated porphyrins as possible therapeutic agents. *J Radioanal Nucl Chem* **2014**;301:269-276.
94. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, **Beiki D**, Hassanzadeh-Rad A, Eftekhari M. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. *Nucl Med Commun* **2014**;35(8):808-817.
95. Hamidieh AA, **Beiki D**, Paragomi P, Fallahi B, Behfar M, Fard-Esfahani A, Hosseini AS, Shamshiri A, Eftekhari M, Ghavamzadeh A. The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131 I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: A pilot study. *Pediatr Transplant* **2014**;18(5):510-517.

96. Fallahi B, Fard-Esfahani A, Hassanzadeh-Rad A, Emami-Ardekani A, **Beiki D**, Eftekhari M. Comparison of transient ischemic dilation ratios in SPECT and SPECT-CT myocardial perfusion imaging in the low pre-test probability group. *Iran J Nucl Med* **2014**;22(2)51-56.
97. Ranjbar S, Bahrami-Samani A, **Beiki D**, Shirvani-Arani S, Ghannadi-Maragheh M. Evaluation of  $^{153}\text{Sm}/^{177}\text{Lu}$ -EDTMP mixture in wild-type rodents as a novel combined palliative treatment of bone pain agent. *J Radioanal Nucl Chem* **2015**;303(1)71-79.
98. Eftekhari M, Anbiaei R, Zamani H, Fallahi B, **Beiki D**, Ameri A, Emami-Ardekani A, Fard-Esfahani A, Gholamrezanezhad A, Razavi Ratki SK, Momen Roknabadi A. Radiation-induced myocardial perfusion abnormalities in breast cancer patients following external beam radiation therapy. *Asia Oceania J Nucl Med Biol* **2015**;3(1)3-9.
99. Ranjbar S, Ghannadi-Maragheh M, Bahrami-Samani A, **Beiki D**. Dosimetric evaluation of  $^{153}\text{Sm}$ -EDTMP,  $^{177}\text{Lu}$ -EDTMP and  $^{166}\text{Ho}$ -EDTMP for systemic radiation therapy: Influence of type and energy of radiation and half life of radionuclides. *Radiat Phys Chem* **2015**;108:60-64.
100. Mozafari S, Erfani M, **Beiki D**, Johari Daha F, Kobarfard F, Balalaie S, Fallahi B. Synthesis and preliminary evaluation of a new  $^{99\text{m}}\text{Tc}$  labeled substance P analogue as a potential tumor imaging agent. *Iran J Pharm Res.* **2015**;14(1):97-110.
101. **Beiki D**, Tajik M, Haddad P, Fallahi B, Arefpour AM, Mirzaei H, Fard-Esfahani A, Emami-Ardekani A, Eftekhari M, Effectiveness and complications of  $^{188}\text{Re}$ -HEDP in palliative treatment of diffuse skeletal metastases. *Iran J Nucl Med* **2015**;23(1):44-48.
102. Aghanejad A, Jalilian AR, Bahrami-Samani A, **Beiki D**, Maus S, khalaj A. Preparation and preliminary biological evaluation of [ $^{153}\text{Sm}$ ] samarium AMD3100; towards a possible therapeutic chemokine receptor CXCR4 targeting complex. *Iran J Nucl Med* **2015**;23(1):36-43.
103. Salehi Y, Fard-Esfahani A, Fallahi B, Aghahosseini F, **Beiki D**, Emami-Ardekani A, Fard-Esfahani P, Ansari M, Eftekhari M. The myocardial perfusion scintigraphy in asymptomatic diabetic patients. *Iran J Nucl Med* **2015**;23(1):27-35.
104. Fard-Esfahani A, Fallahi B, Karimi M, **Beiki D**, Saghari M, Emami-Ardekani A, Fard-Esfahani P, Ansari M, Eftekhari M. Changes in salivary gland function following radioiodine therapy of thyroid diseases: A comparison of high-dose therapy for thyroid cancer and low-dose therapy for benign thyroid disease. *Iran J Nucl Med* **2015**;23(1):1-7.
105. Chavoshi M, Fard-Esfahani A, Fallahi B, Emami-Ardekani A, **Beiki D**, Hassanzadeh-Rad A, Eftekhari M. Assessment of prognostic value of semiquantitative parameters on gated single photon emission computed tomography myocardial perfusion scintigraphy in a large middle eastern population. *Indian J Nucl Med* **2015**;30(3):233-238.
106. Mirzaei A, Jalilian AR, Aghanejad A, Mazidi M, Yousefnia H, Shabani G, Ardaneh K, Geramifar P, **Beiki D**. Preparation and evaluation of  $^{68}\text{Ga}$ -ECC as a PET renal imaging agent. *Nucl Med Mol Imaging* **2015**;49:208-216.
107. Mirzaei A, Jalilian AR, Badbarin A, Mazidi M, Morshojaei F, Geramifar P, **Beiki D**. Optimized production and quality control of  $^{68}\text{Ga}$ -EDTMP for small clinical trials. *Ann Nucl Med* **2015**;29(6):506-11.
108. Vahidfar S, Jalilian AR, Fazaeli Y, Bahrami-Samani A, **Beiki D**, Khalaj A. Preparation of a  $^{153}\text{Sm}$ -5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin complex as a possible therapeutic agent. *Iran J Nucl Chem* **2015**;23(2):65-72.

109. **Beiki D**, Karami F, Fallahi B, Kaviani A, Harirchi I, Omranipour R, Erfani M, Farzanefar S, Fard-Esfahani A, Emami-Ardekani A, Saghari M, Eftekhari M. Evaluation of a new  $^{99m}\text{Tc}$ -Bombesin analog in differentiation of malignant from benign breast tumors. *Iran J Nucl Chem* **2015**;23(2):103-107.
110. Shamshirian D, Erfani M, **Beiki D**, Fallahi B, Shafiei M. Development of a  $^{99m}\text{Tc}$ -labeled lactam bridge-cyclized alpha-MSH derivative peptide as a possible single photon imaging agent for melanoma tumors. *Ann Nucl Med* **2015**;29:709-20.
111. Emami-Ardekani A, Esteghamati A, Farzanefar S, Abousaidi M, Abbasi M, Abdollahi S, Fallahi B, **Beiki D**, Fard-Esfahani A, Nakhjavani M, Eftekhari M. Folate therapy improves the stress-to-rest mean LV volume ratio in myocardial perfusion imaging in patients with diabetes. *Ann Nucl Med* **2015**;29(8):740-4.
112. Aghanejad A, Jalilian AR, Bolourinovin F, Mirzaee A, Abdi K, Erfani M, **Beiki D**, Maus S, Khalaj A. Preparation and Quality Control of  $^{111}\text{In}$ -Plerixafor for Chemokine Receptor CXCR4. *Recent Patents and Topics on Imaging* **2015**;5(1):26-30.
113. Ranjbar H, Bahrami-Samani A, **Beiki D**, Ghannadi-Maraghes M. Investigation of radial dose distribution and cumulative dose of radiopharmaceuticals used for pain palliation of bone metastases. *J Nucl Sci Technol* **2015**;73:42-47.
114. Fallahi B, Esmaeili A, **Beiki D**, Oveisgharan S, Noorollahi-Moghaddam H, Erfani M, Tafakhori A, Rohani M, Fard-Esfahani A, Emami-Ardekani A, Geramifar P, Eftekhari M. Evaluation of  $^{99m}\text{Tc}$ -TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders. *Ann Nucl Med* **2016**;30(2):153-62.
115. Khoshbakht S, Kobarfard F, **Beiki D**, Sabzevari O, Amini M, Mehrnejad F, Tabib K, Shahhosseini S. HYNIC a bifunctional prosthetic group for the labelling of peptides with  $^{99m}\text{Tc}$  and  $^{18}\text{F}$ FDG. *J Radioanal Nucl Chem* **2016**;307:1125-34.
116. Aghanejad A, Jalilian AR, Maus S, Yousefnia H, Geramifar P, **Beiki D**. Optimized production and quality control of  $^{68}\text{Ga}$ -DOTATATE. *Iran J Nucl Med* **2016**;24(1):29-36.
117. Mirzaei A, Jalilian AR, Shabani G, Mazidi M, Akhlaghi M, **Beiki D**. Development of  $^{68}\text{Ga}$  Ethyl Cysteinate Dimer for PET studies. *J Radioanal Nucl Chem* **2016**;307:725-732.
118. Mirzaei A, Jalilian AR, Akhlaghi M, **Beiki D**. Production of  $^{68}\text{Ga}$ -citrate based on a  $\text{SnO}_2$  generator for short-term turpentine oil-induced inflammation imaging in rats. *Curr Radiopharm.* **2016** May 6. [Epub ahead of print]
119. Jalilian AR, **Beiki D**, Hassanzadeh-Rad A, Eftekhari A, Geramifar P, Eftekhari M. Production and clinical applications of radiopharmaceuticals and medical radioisotopes in Iran. *Semin Nucl Med.* **2016**;46(4):340-358
120. Khoshbakht S, **Beiki D**, Geramifar P, Kobarfard F, Sabzevari O, Amini M, Mehrnejad F, Shahhosseini S. Synthesis, radiolabeling, and biological evaluation of peptide LIKKPF functionalized with HYNIC as apoptosis imaging agent. *Iran J Pharm Res.* **2016**;15(2):415-424.
121. Fard-Esfahani A, Marzban M, Emami-Ardekani A, Hassanzadeh-Rad A, Fallahi B, **Beiki D**, Geramifar P, Eftekhari M. Spinal cord metastasis from testicular seminoma detected by F-18 FDG PET/CT study prior to neurological symptoms: An unusual presentation. *Iran J Nucl Med.* **2016**;24(2):146-148.

122. Katal S, Hassanzadeh-Rad A, Eftekhari M, Fard-Esfahani A, **Beiki D**, Fallahi B, Emami-Ardekani A, Abbasi M. Two-day stress-rest lower limbs perfusion scan in patients referred for myocardial perfusion imaging. *Iran J Nucl Med.* 2016;24(2):120-128.
123. Razavi Ratki SK, Fallahi B, Namiranian N, Emami-Ardekani A, Saghari M, Mirabzadeh A, Fard-Esfahani A, **Beiki D**, Eftekhari M, Pooyafard F. Factors affecting the quality of life of well-differentiated thyroid carcinoma patients: A cross-sectional study on 435 Iranian patients. *Iran J Nucl Med.* 2016;24(2):92-97.
124. Khoshbakht S, **Beiki D**, Geramifar P, Kobarfard F, Sabzevari O, Amini M, Shahhosseini S. 18FDG-labeled LIKPF: a PET tracer for apoptosis imaging. *J Radioanal Nucl Chem.* 2016;310:413-421.
125. Jalilian AR, **Beiki D**. The present status of radiopharmaceuticals in the country. *Iran J Pharm Res.* 2016;15(3):257-259.
126. Shamshirian D, Erfani M, **Beiki D**, Hajiramazanali M, Fallahi B. A 99mTc-tricine-HYNIC-labeled peptide targeting the melanocortin-1 receptor for melanoma imaging. *Iran J Pharm Res.* 2016;15(3):349-360.
127. Sharifi M, Yousefnia H, Zolghadri S, Bahrami-Samani A, Naderi M, Jalilian AR, Geramifar P, **Beiki D**. Preparation and biodistribution assessment of 68Ga-DKFZ-PSMA-617 for PET prostate cancer imaging. *Nucl Sci Tech.* 2016;27(6):142.
128. Fallahi B, **Beiki D**, Salehi Y, Emami-Ardekani A, Fard-Esfahani A, Aghahosseini F, Haghhighatafshar M, Eftekhari M. Reverse perfusion pattern in myocardial perfusion imaging using technetium-99m-sestamibi in patients with intermediate risk for coronary artery disease in relation to the time of acquisition and intensity of visceral uptake as artifactual causes. *Nucl Med Commun.* 2017;38(1):15-20.
129. Ranjbar H, Bahrami-Samani A, Beiki D, Ghannadi-Maragheh M. Development of 153Sm/177Lu-EDTMP as a possible therapeutic complex. *Iran J Nucl Med.* 2017;25(1):11-16.
130. Fallahi B, Fard-Esfahani A, Emami-Ardekani A, Sahari S, **Beiki D**, Hassanzadeh-Rad A, Abedi SM, Geramifar P, Eftekhari M. How to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation? *Iran J Nucl Med.* 2017;25(1):51-59.
131. Farzanefar S, Abbasi M, **Beiki D**. Sentinel lymph node biopsy correctly predicts regional lymph node recurrence in trunk malignant melanoma with multiple drainage basins. *Iran J Nucl Med.* 2017;25(1):77-80.
132. Gholipour N, Akhlaghi M, Mokhtari Kheirabadi A, **Beiki D**, Geramifar P, Yousefnia H, Mazidi M. Chelator-free radiolabeling of dextran with 68Ga for PET studies. *J Radioanal Nucl Chem.* 2017; doi: 10.1007/s10967-016-5164-z.
133. Eftekhari M, Kalantari F, Emami-Ardekani A, Amini H, Fard-Esfahani A, Fallahi B, **Beiki D**, Farzanefar S, Kalantari E, Hasanzadeh-Rad A, Abbasi M. Radiation induced myocardial perfusion abnormalities in patients with left breast cancer: A prospective study with short and long term follow up. *Iran J Nucl Med.* 2017;25(Suppl 1):21-25.
134. Fallahi B, Moasses-Ghafari B, Fard-Esfahani A, Geramifar P, **Beiki D**, Emami-Ardekani A, Eftekhari M. Factors influencing the pattern and intensity of myocardial 18F-FDG uptake in oncologic PET-CT imaging. *Iran J Nucl Med.* 2017;25(Suppl 1):52-61.

135. Kumar P, Roselt P, Reischl G, Cullinane C, **Beiki D**, Ehrlichmann W, Binns D, Naimi E, Yang J, Hicks R, Machulla HJ, Wiebe LI.  $\beta$ -[18F]Fluoro Azomycin Arabinoside ( $\beta$ -[18F]FAZA): Synthesis, radiofluorination and preliminary PET imaging of murine A431 tumors. *Curr Radiopharm.* 2017;10(2):93-101.
136. Sharifi M, Yousefnia H, Bahrami-Samani A, Jalilian AR, Zolghadri S, Alirezapour B, Geramifar P, Maus S, **Beiki D**. Optimized production, quality control, biological evaluation and PET/CT imaging of  $^{68}\text{Ga}$ -PSMA-617 in breast adenocarcinoma model. *Radiochim Acta.* 2017;105(5):399-408.
137. Mottaghitalab F, Kiani M, Farokhi M, Kundu SC, Reis RL, Gholami M, Bardania H, Dinarvand R, Geramifar P, **Beiki D**, Atyabi F. Targeted delivery system based on gemcitabine loaded silk fibroin nanoparticles for lung cancer therapy. *ACS Appl Mater Interfaces.* 2017;9(37):31600–31611.
138. Shanehsazzadeh S, Jalilian AR, Lahooti A, Geramifar P, **Beiki D**, Yousefnia H, Rabiee A, Mazidi M, Mirshojaei SF, Maus S. Preclinical evaluation of  $^{68}\text{Ga}$ -MAA from commercial available  $^{99\text{m}}\text{Tc}$ -MAA. *Iran J Pharm Res.* 2017;16(14):1415-23.
139. Zolghadri S, Naderi M, Yousefnia H, Alirezapour A, **Beiki D**. Evaluation of the possible utilization of  $^{68}\text{Ga}$ -DOTATOC in diagnosis of adenocarcinoma breast cancer. *Asia Ocean J Nucl Med Biol.* 2018;6(1):41-9.
140. Beiki D. A quarter of a century with Iranian Journal of Nuclear Medicine. *Iran J Nucl Med.* 2018;26(1):1.
141. Farzanefar S, Etemadi R, Shirkhoda M, Mahmoodzadeh H, Erfani M, Fallahi B, Abbasi M, Ayati N, Hassanzadeh-Rad A, Eftekhari M, **Beiki D**. The value of Technetium-99m labeled alpha-Melanocyte-Stimulating Hormone ( $^{99\text{m}}\text{Tc}$ - $\alpha$ -MSH) in diagnosis of primary and metastatic lesions of malignant melanoma. *Asia Ocean J Nucl Med Biol.* 2018;6(2):155-60.
142. Emami-Ardekani A, Mirzabeigi A, Fard-Esfahani A, Fallahi B, **Beiki D**, Hasanzadeh A, Geramifar P, Eftekhari M. Comparing diagnostic performance of  $^{131}\text{I}$ -metaiodobenzylguanidine ( $^{131}\text{I}$ -MIBG) and  $^{99\text{m}}\text{Tc}$ -hydrazinonicotinyl-Tyr3-Octreotide ( $^{99\text{m}}\text{Tc}$ -HYNIC-TOC) in diagnosis and localization of pheochromocytoma and neuroblastoma. *Iran J Nucl Med.* 2018;26(2):68-75.
143. Mosayebnia M, Rezaeianpour S, Rikhtechi P, Hajimahdi Z, **Beiki D**, Kobarfard F, Sabzevari O, Amini M, Abdi K, Shahhosseini S. Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods. *Iran J Pharm Res.* 2018;17(3):917-26.
144. Fallahi B, **Beiki D**, Salehi Y, Salehi Y, Emami-Ardekani A, Fard-Esfahani A, Aghahosseini F, Eftekhari M. Benefits of combined pharmacologic and submaximal exercise stress on Sub-diaphragmatic activity in myocardial perfusion scintigraphy. *Iran J Nucl Med.* 2018;26(2):105-111.
145. Eftekhari M, Abbasi M, Tarafdari A, Emami-Ardekani A, Farzanefar S, Kalantari F, Fallahi B, Fard-Esfahani A, **Beiki D**, Naseri M, Saghari M. Automated interpretation of myocardial perfusion images with multilayer perceptron network as a decision support system. *J Med Imaging Health Inform.* 2018;8(9):1844-49.
146. Fard-Esfahani A, **Beiki D**, Harsini S, Emami-Ardekani A, Fallahi B, Eftekhari M. Absent radiotracer uptake in thyroid gland in parathyroid scintigraphy with  $^{99\text{m}}\text{Tc}$ -MIBI: A case report. *Iran J Nucl Med.* 2019;27(2):142-145.
147. Almasi T, Jabbari K, Gholipour N, Mokhtari Kheirabadi A, **Beiki D**, Shahrokhi P, Akhlaghi M. Synthesis, characterization, and in vitro and in vivo  $^{68}\text{Ga}$  radiolabeling of thiosemicarbazone Schiff

base derived from dialdehyde dextran as a promising blood pool imaging agent. *Int J Biol Macromol.* 2019;125:915-21.

148. Gholipour N, Akhlaghi M, Mokhtari Kheirabadi A, Fasihi Ramandi M, Farashahi A, **Beiki D**, Jalilian AR. Development of a novel <sup>68</sup>Ga-dextran carboxylate derivative for blood pool imaging. *Radiochim Acta* 2019; 107(3): 233–242.
149. Hajiramezanali M, Atyabi F, Mosayebnia M, Akhlaghi M, Geramifar P, Jalilian AR, Mazidi SM, Yousefnia H, Shahhosseini S, **Beiki D**. <sup>68</sup>Ga-Radiolabeled bombesin conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and biological evaluation. *Int J Nanomedicine* 2019;14: 2591-2605.
150. Khoshbakht S, **Beiki D**, Geramifar P, Kobarfard F, Sabzevari O, Amini M, Bolourchian N, Shamshirian D, Shahhosseini S. Design, synthesis, radiolabeling, and biologic evaluation of three <sup>18</sup>F-FDG-radiolabeled targeting peptides for the imaging of apoptosis. *Cancer Biother Radiopharm.* 2019;34(5):271-9.
151. Fallahi B, Manafi-Farid R, Eftekhari M, Fard-Esfahani A, Geramifar P, Akhlaghi M, Hashemi Taheri AP, **Beiki D**. Diagnostic efficiency of <sup>68</sup>Ga-DOTATATE PET/CT as compared to <sup>99m</sup>Tc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors. *Asia Ocean J Nucl Med Biol.* 2019;7(2):129-140.
152. Jokar S, Khazaei S, Behnammanesh H, Shamloo A, Erfani M, **Beiki D**, Bavi O. Recent advances in the design and applications of amyloid- $\beta$  peptide aggregation inhibitors for Alzheimer's disease therapy. *Biophys Rev.* 2019;11(6):901-905.
153. Behnammanesh H, Jokar S, Erfani M, Geramifar P, Sabzevari O, Amini M, Mazidi SM, Hajiramazanali M, **Beiki D**. Design, preparation and biological evaluation of a <sup>177</sup>Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors. *Bioorg Chem.* 2020;94:103381.
154. Shahrokhi P, Emami-Ardekani A, Harsini S, Eftekhari M, Fard-Esfahani A, Fallahi B, Karamzade Ziarati N, Akhlaghi M, Farzaneifar S, Hashemi Taheri AP, **Beiki D**. <sup>68</sup>Ga-DOTATATE PET/CT compared with <sup>131</sup>I-MIBG SPECT/CT in the evaluation of neural crest tumors. *Asia Ocean J Nucl Med Biol.* 2020;8(1):8-17.
155. Fard-Esfahani A, Valipouri MR, Harsini S, **Beiki D**, Emami-Ardekani A, Fallahi B, Eftekhari M. <sup>68</sup>Ga-DOTATATE PET/CT compared with <sup>131</sup>I-MIBG SPECT/CT in the evaluation of neural crest tumors. *Iran J Nucl Med.* 2020;28(1):14-20.
156. Mosayebnia M, Hajimahdi Z, **Beiki D**, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen. *Bioorg Chem.* 2020;99:103743.
157. Pirooznia N, Abdi K, **Beiki D**, Emami F, Arab SS, Sabzevari O, Pakdin-Parizi Z, Geramifar P, Ghassemi Tabassi E. Radiosynthesis, biological evaluation and preclinical study of a <sup>68</sup>Ga-labeled cyclic RGD peptide as an early diagnostic agent for overexpressed  $\alpha v \beta 3$  integrin receptors in non-small cell lung cancer. *Contrast Media Mol Imaging.* 2020;2020: 8421657.
158. Behnammanesh H, Erfani M, Hajiramazanali M, Jokar S, Geramifar P, Sabzevari O, Amini M, Mazidi M, **Beiki D**. Preclinical study of a new <sup>177</sup>Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells. *Asia Ocean J Nucl Med Biol.* 2020;8(2):109-115.

159. Gholipour N, Akhlaghi M, Mokhtari Kheirabadi A, Geramifar P, **Beiki D**. Development of Ga-68 labeled, biotinylated thiosemicarbazone dextran-coated iron oxide nanoparticles as multimodal PET/MRI probe. *Int J Biol Macromol*. 2020;138: 932-941.
160. Fard-Esfahani A, Valipouri MR, Harsini S, **Beiki D**, Emami-Ardekani A, Fallahi B, Eftekhari M. Predictors of success of the ablative/therapeutic radioiodine (<sup>131</sup>I) in differentiated thyroid cancer. *Iran J Nucl Med*. 2020;28(1):14-20.
161. Pirooznia N, Abdi K, **Beiki D**, Emami F, Arab SS, Sabzevari O, Soltani-Gooshkhaneh S. <sup>177</sup>Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: biological evaluation and preclinical study. *Bioorg Chem*. 2020;102:104100.
162. Jokar S, Behnammanesh H, Erfani M, Sharifzadeh M, Gholami M, Sabzevari O, Amini M, Geramifar P, Hajiramazanali M, **Beiki D**. Synthesis, biological evaluation and preclinical study of a novel <sup>99m</sup>Tc-peptide: A targeting probe of amyloid-beta plaques as a possible diagnostic agent for Alzheimer's disease. *Bioorg Chem*. 2020;99: 103857.
163. Jokar S, Erfani M, Bavi O, Khazaei S, Sharifzadeh M, Hajiramazanali M, **Beiki D**, Shamloo A. Design of peptide-based inhibitor agent against amyloid- $\beta$  aggregation: Molecular docking, synthesis and in vitro evaluation. *Bioorg Chem*. 2020;102: 104050.
164. Harsini S, Fallahi B, Karamzade-Ziarati N, Amini E, Emami-Ardekani A, Fard-Esfahani A, Kardoust Parizi M, Farzanefar S, **Beiki D**. A Prospective Study on [<sup>68</sup>Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer. *Asia Ocean J Nucl Med Biol*. 2021;9(2):101-110.
165. Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, Eftekhari M, **Beiki D**. <sup>99m</sup>Tc-PSMA SPECT/CT Versus <sup>68</sup>Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer. *Clin Nucl Med*. 2021;46(2): e68-e74.
166. Almasi T, Gholipour N, Akhlaghi M, Mokhrari Kheirabadi A, Mazidi SM, Hosseini SH, Geramifar P, **Beiki D**, Rostampour N, Shahbazi Gahrouei D. Development of Ga-68 radiolabeled DOTA functionalized and acetylated PAMAM dendrimer-coated iron oxide nanoparticles as PET/MR dual-modal imaging agent. *Int J Polym Mater*. 2021;70(15):1077-1089.
167. Fard-Esfahani A, Saidi B, Emami-Ardekani A, Fallahi B, **Beiki D**, Mirshahvalad SA, Eftekhari M. Adrenal lesions: Common findings and pitfalls on <sup>18</sup>F-FDG PET/CT. *Iran J Nucl Med*. 2021;29(2):97-103.
168. Haghighi F, Manafi-Farid R, Emami-Ardekani A, **Beiki D**. Disseminated thoracoabdominal splenosis mimicking metastatic disease: A case of colorectal cancer. *Iran J Nucl Med*. 2022;30(1):72-75.
169. Rezaei Aghdam H, Bitarafan Rajabi A, Sadat Ebrahimi SE, **Beiki D**, Abdi KH, Mousavi Motlagh SS, Kiani Dehkordi B, Darbandi Azar A, Shafiee Ardestani M. <sup>18</sup>F-FDG microPET and MRI targeting breast cancer mouse model with designed synthesis nanoparticles. *J Nanomater*. 2022;2022: 5737835.
170. Emami-Ardekani A, Ghorbani-Nik F, Karamzade-Ziarati N, Manafi-Farid R, Fard-Esfahani A, Fallahi B, **Beiki D**, Salehi Y, Eftekhari M. Impact of TSH stimulation on <sup>2</sup>-[<sup>18</sup>F]FDG PET/CT results in patients with papillary thyroid carcinoma presented with elevated serum thyroglobulin level and negative diagnostic iodine-131 whole-body scan. *Iran J Nucl Med*. 2022;30(2):88-95.

171. Al-Timimi A, Manafi-Farid R, Fallahi B, **Beiki D**, Askari E, Rezaei A, Adinehpour Z, Eftekhari M. Factors predicting the early biochemical response to [177Lu]Lu-PSMA therapy in patients with metastatic castration resistant prostate cancer. *Iran J Nucl Med.* 2022;30(2):115-121.
172. Heidari S, Akhlaghi M, Sadeghi M, Mokhtari Kheirabadi A, **Beiki D**, Emami-Ardekani A, Rouhollah A, Saeidzadeh P, Soleyman R. Development of 64Cu-DOX/DOX-loaded chitosan-BSA multilayered hollow microcapsules for selective lung drug delivery. *J Drug Deliv Sci Technol.* 2022;73:103477.
173. Najdian A, Amanlou M, **Beiki D**, Bitarafan-Rajabi A, Mirzaei M, Shafiee Ardestani M. Amino-modified-silica-coated gadolinium-copper nanoclusters, conjugated to AS1411 aptamer and radiolabeled with technetium-99 m as a novel multimodal imaging agent. *Bioorg Chem.* 2022;125:105827.
174. Emami-Ardekani A, Karamzade-Ziarati N, Salehi Y, Manafi-Farid R, Fard-Esfahani A, Geramifar P, **Beiki D**, Akhlaghi M, Fallahi B. Nuclear imaging in patients with differentiated thyroid cancer and negative radioactive iodine scan. *Iran South Med J.* 2022; 25(4):394-407.
175. Hassanzadeh-Rad A, Kavosi H, Karamzade-Ziarati N, Fallahi B, Jamshidi AR, Emami-Ardekani A, **Beiki D**, Eftekhari M. Diagnostic agreement between clinical criteria and disease activity in Takayasu's arteritis by 2-[18F]FDG PET-CT scan. *Iran J Nucl Med.* 2023;31(1):11-19.
176. Fallahi B, Moharrami K, Beiki D, Fard-Esfahani A, Alimoghaddam K, Eftekhari M. Clinical benefit and quality of life during low-dose sorafenib maintenance therapy in radioiodine refractory differentiated thyroid cancer patients: A historical cohort study. *Iran J Nucl Med.* 2023;31(1):42-48.
177. Zolghadri S, Badipa F, Amraee N, Alirezapour B, Beiki D, Yousefnia H. Development and evaluation of [64Cu]Cu-DOTATATE for clinical applications. 2023; 31(2): 157-166.
178. Pirooznia N, Abdi K, Beiki D, Emami F, Vosoughi H. Preparation and preclinical evaluation of a Gd(III)-RGD peptide for MR molecular imaging in non-small cell lung carcinoma (NSCLC). *Iran J Nucl Med.* 2023;31(2):144-150.
179. Heidari S, Sadeghi M, Akhlaghi M, Beiki D, Yazdi SI. Internal dosimetry of 64Cu-DOX-loaded microcapsules by Monte Carlo method. *Appl Radiat Isot.* 2023 Jun:196:110788.
180. Mirshahvalad SA, Manafi-Farid R, Fallahi B, Seifi S, Geramifar P, Emami-Ardekani A, Eftekhari M, Beiki D. Diagnostic value of [68Ga]Ga-Pentixafor versus [18F]FDG PET/CTs in non-small cell lung cancer: a head-to-head comparative study. *Nucl Med Commun.* 2023 Sep 1;44(9):803-809.
181. Beiki D. Iranian Journal of Nuclear Medicine got an impact factor by the Clarivate Analytics (Web of Science) entering the fourth decade of publication. *Iran J Nucl Med.* 2024; 32(1): 1-2.
182. Manafi-Farid R, Mahini M, Mirshahvalad SA, Fallahi B, Fard-Esfahani A, Emami-Ardekani A, Eftekhari M, Mousavi SA, Beiki D. Diagnostic value of [68Ga]Ga-Pentixafor PET/CT in malignant melanoma: A pilot study. *Nucl Med Commun.* 2024 Mar 1;45(3):221-228.
183. Ebrahimi F, Reisi Zargari N, Akhlaghi M, Asghari SM, Abdi K, Balalaie S, Asadi M, Beiki D. Synthesis, radiolabeling, and biodistribution study of a novel DOTA-peptide for targeting vascular endothelial growth factor receptors in the molecular imaging of breast cancer. *Pharmaceutics.* 2024;16(7):899. Doi: 10.3390/pharmaceutics16070899.
184. Kiani M, Jokar S, Hassanzadeh L, Behnammanesh H, Bavi O, Beiki D, Assadi M. Recent clinical implications of FAPI: Imaging and therapy. *Clin Nucl Med.* 2024 Jul 18. doi: 10.1097/RLU.0000000000005348.

185. Reisi Zargari N, Ebrahimi F, Akhlaghi M, Beiki D, Abdi K, Abbasi MA, Ramezanpour S, Asghari SM. Novel Gd-DTPA-peptide for targeted breast tumor magnetic resonance imaging. *Biomed Pharmacother.* 2024 Sep;178:117189. doi: 10.1016/j.biopha.2024.117189.
186. Najdian A, Beiki D, Abbasi M, Gholamrezanezhad A, Ahmadzadehfar H, Amani AM, Shafiee Ardestani M, Assadi M. Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications. *Cancer Imaging.* 2024;24:127. Doi: 0.1186/s40644-024-00762-z.

## ABSTRACTS AND PRESENTATIONS

### International Congresses [English]

1. **Diagnostic Radiopharmaceuticals.** International Conference on Nuclear Science and Technology, Isfahan, Iran, 6-8 May, 2024.
2. **Evaluation of the intermolecular interactions between the peptide- based inhibitors and amyloid- $\beta$  monomer/fibril structures.** 44th Meeting of Australian Society for Biophysics, Sydney, Australia, 2-4 December, 2020.
3. **Association between  $^{18}\text{F}$ -FDG PET/CT findings and bone mineral densitometry results.** 32nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 12-16 October, 2019.
4. **Role of  $^{99\text{m}}\text{Tc}$ - $\alpha$ -MSH Scan in Diagnosis of Malignant Melanoma,** 31st Annual Congress of the European Association of Nuclear Medicine, Düsseldorf, Germany, 13-17 October, 2018.
5. **Association between gastric FDG uptake in PET-CT and 14-C UBT results in patients referred for non-gastric cancer PET-CT studies,** 30th Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria, 21-25 October, 2017.
6. **Diagnostic nuclear medicine procedures and resulting radiation dose of Tehran population in 2011-2014,** 29th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 15-19 October, 2016.
7. **Factors Influencing the Pattern and Intensity of Myocardial FDG Uptake in Oncologic PET-CT Imaging,** 29th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 15-19 October, 2016.
8. **Comparison of sensitivity and specificity of Tc-99m octreotide and I-131 MIBG scintigraphies in diagnosis and localization of pheochromocytoma and neuroblastoma,** 29th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 15-19 October, 2016.
9. **Association between FDG-PET/CT Findings and Tumor Markers in Patients with Colorectal Carcinoma,** 29th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 15-19 October, 2016.
10. **Preparation and biological evaluation of  $^{99\text{m}}\text{Tc}$ -HYNIC-LIKKPF for the detection of apoptosis,** 29th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 15-19 October, 2016.
11.  **$^{18}\text{F}$ -FDG-Aoe-LIKKP-Pyr-A: A new peptide radiotracer for apoptosis imaging,** 29th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 15-19 October, 2016.

12. **Early and late follow-up myocardial perfusion scan in patients with breast cancer after external radiotherapy**, 29th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 15-19 October, 2016.
13. **Efficacy and complications of  $^{153}\text{Sm}$ -EDTMP added to palliative local radiotherapy for bone metastases**, San Francisco, USA, 27-29 June, 2016.
14. **Preliminary report of long term follow-up with myocardial perfusion scan in breast cancer patients after external beam radiation therapy**, 28th Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 10-14 October, 2015.
15. **Evaluation of  $^{99\text{mTc}}$ -TRODAT-1 SPECT in the diagnosis of Parkinson's disease and its differentiation from the other types of parkinsonism syndromes - A pilot study**, 28th Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 10-14 October, 2015.
16. **Effect of I-131 MIBG thyroid uptake on thyroid function tests**, 28th Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 10-14 October, 2015.
17. **New lactam bridge  $^{99\text{mTc}}$ - $\alpha$  -melanocyte-stimulating hormone analog for diagnosis of metastatic melanoma**, 28th Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 10-14 October, 2015.
18. **Synthesis and radiolabeling of HYNIC-conjugated LIKKPF peptide with  $^{18\text{F}}$ -FDG for the detection of apoptosis**, 28th Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 10-14 October, 2015.
19. **Assessment of prognosis in differentiated thyroid carcinoma patients showing detectable thyroglobulin level 6 months after therapy based on radioactive iodine whole body scan results (A preliminary report)**, 28th Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 10-14 October, 2015.
20. **Radioiodine retreatment or wait for a limited time in patients with differentiated thyroid carcinoma with negative thyroglobulin and antithyroglobulin, but remained thyroid residue after post-surgery radioiodine ablative therapy**, 28th Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 10-14 October, 2015.
21. **Preparation and evaluation of  $^{68}\text{Ga}$ -ECC as a PET renal imaging agent**, 45th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), Brisbane, Australia, 17-20 April, 2015.
22. **Preparation and preliminary biological evaluation of [ $^{153}\text{Sm}$ ] samarium AMD3100; towards a possible therapeutic chemokine receptor CXCR4 targeting complex**, 27th Annual Congress of the European Association of Nuclear Medicine, Gothenburg, Sweden, 18-22 October, 2014.
23. **Relationship between myocardial perfusion indices and mechanical dyssynchrony based on gated SPECT phase analyses in patients with coronary artery disease and heart failure**, 11th Congress of World Federation of Nuclear Medicine & Biology, Cancun, Mexico, 27-31 September, 2014.
24. **Radionuclide bone pain palliation, experience in Iran**, 11th Congress of World Federation of Nuclear Medicine & Biology, Cancun, Mexico, 27-31 September, 2014.

25. **Radiosynthesis and biodistribution studies of [62Zn/62Cu]-Plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging**, 11th Congress of World Federation of Nuclear Medicine & Biology, Cancun, Mexico, 27-31 September, 2014.
26. **Synthesis and preliminary evaluation of a new 99mTc labeled substance P analogue as a potential tumor imaging agent**, 11th Congress of World Federation of Nuclear Medicine & Biology, Cancun, Mexico, 27-31 September, 2014.
27. **Evaluation of a new 99mTc-Bombesin analog in differentiation of malignant from benign breast tumors**, 11th Congress of World Federation of Nuclear Medicine & Biology, Cancun, Mexico, 27-31 September, 2014.
28. **Evaluation of 188Re-HEDP efficacy in metastatic bone pain palliation therapy**, 11th Congress of World Federation of Nuclear Medicine & Biology, Cancun, Mexico, 27-31 September, 2014.
29. **Quality of life and associated factors in radio-iodine treated patients with differentiated thyroid carcinoma**, 26th Annual Congress of the European Association of Nuclear Medicine, Lyon, France, 19-23 October, 2013.
30. **Comparison of Salivary Gland Function Side Effect of 30-100 mCi versus <30 mCi of Radioiodine Therapy**, 26th Annual Congress of the European Association of Nuclear Medicine, Lyon, France, 19-23 October, 2013.
31. **Preliminary report of randomized clinical trial for assessment of the short term Folate therapy on transient ischemic dilatation in myocardial perfusion scan of diabetic patients**, 26th Annual Congress of the European Association of Nuclear Medicine, Lyon, France, 19-23 October, 2013.
32. **Evaluation of myocardial perfusion and function after kidney transplantation by gated myocardial perfusion scintigraphy**, 25th Annual Congress of the European Association of Nuclear Medicine, Milan, Italy, 27-31 October, 2012.
33. **The Influence of resolution recovery during image reconstruction on quantitative brain SPECT imaging**, 25th Annual Congress of the European Association of Nuclear Medicine, Milan, Italy, 27-31 October, 2012.
34. **Comparative evaluation of the diagnostic accuracy of Tc-99m-sestamibi gated SPECT using five different sets of image acquisitions at stress and rest phases for the diagnosis of coronary artery disease**, 25th Annual Congress of the European Association of Nuclear Medicine, Milan, Italy, 27-31 October, 2012.
35. **Evaluation of 99mTc-Bombesin in differentiation of malignant from benign breast tumors**, 25th Annual Congress of the European Association of Nuclear Medicine, Milan, Italy, 27-31 October, 2012.
36. **The value of quantitative myocardial perfusion scintigraphy using 99mTc-MIBI ECG-Gated SPECT for determining the clinical prognosis in patients suspicious for coronary artery disease**, 25th Annual Congress of the European Association of Nuclear Medicine, Milan, Italy, 27-31 October, 2012.
37. **Evaluation of 99mTc-Ubiquicidin 29-41 scintigraphy in differentiation of bacterial infection from sterile inflammation in diabetic foot**, 24th Annual Congress of the European Association of Nuclear Medicine, Birmingham, UK, 15-19 October, 2011.
38. **Evaluation of treatment efficacy of metastatic bone pain with 153Sm-EDTMP**, 24th Annual Congress of the European Association of Nuclear Medicine, Birmingham, UK, 15-19 October, 2011.

39. **Evaluation of  $^{99m}\text{Tc}$ -Ubiquicidin scintigraphy in differentiation of bacterial infection from sterile inflammation in suspected orthopedic implants**, 24th Annual Congress of the European Association of Nuclear Medicine, Birmingham, UK, 15-19 October, 2011.
40. **Estimates of renal function by modification of diet for renal disease equation in Iranian patients with acute renal failure**, 24th Annual Congress of the European Association of Nuclear Medicine, Birmingham, UK, 15-19 October, 2011.
41. **Nasolacrimal Duct Obstruction as a Complication of Iodine-131 Therapy in Patients with Thyroid Cancer**, 24th Annual Congress of the European Association of Nuclear Medicine, Birmingham, UK, 15-19 October, 2011.
42. **The role of technetium-99m ECD SPECT in the evaluation of long-term outcome after mild traumatic brain injury**, 24th Annual Congress of the European Association of Nuclear Medicine, Birmingham, UK, 15-19 October, 2011.
43. **Predicting factors of successful postsurgical remnant ablation with I-131 in patients with differentiated thyroid carcinoma**, 23rd Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria, 9-13 October, 2010.
44. **The effect of radioiodine treatment on the development of second primary cancer in patients with differentiated thyroid carcinoma**, 23rd Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria, 9-13 October, 2010.
45. **Scintigraphic pattern of bone metastases in 146 patients with different types of cancers**, 23rd Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria, 9-13 October, 2010.
46. **The precision of Cockcroft-Gault formula for estimation of glomerular filtration rate in acute renal failure in comparison with double plasma sample method using Tc-99m DTPA**, 23rd Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria, 9-13 October, 2010.
47. **Is gall bladder ejection fraction using fatty meal CCK cholescintigraphy useful for diagnosis of chronic cholecystitis**, 23rd Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria, 9-13 October, 2010.
48. **Diffusion of nuclear medicine in developing countries: the obstacles and barriers**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
49. **Is gall bladder ejection fraction using fatty meal CCK cholescintigraphy useful for diagnosis of chronic cholecystitis**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
50. **Radiation synovectomy, effectiveness of P-32 in treatment of chronic haemophilic synovitis**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
51. **Controversies in treatment of differentiated thyroid carcinoma, concerns regarding response vs adverse effects of I-131**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
52. **Echocardiographic left ventricular functional changes in subclinical hyperthyroidism and acute hypothyroidism in patients with thyroid cancer**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010

53. **In vitro tracking of  $^{111}\text{In}$ -Oxine labeled mesenchymal stem cells following intravenous infusion in patients with advanced cirrhosis**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
54. **The value of transient ischemic dilatation in the presence of normal myocardial perfusion**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
55. **The brain perfusion pattern in non-medicated schizophrenic patients**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
56. **P-Glycoprotein assay and  $^{99\text{mTc}}$ -MIBI imaging in relation to multiple drug resistance in patients with multiple myeloma**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
57. **SPECT vs. planar scintigraphy with  $^{99\text{mTc}}$ -RBC for diagnosis of liver hemangioma**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
58. **Planning a new policy based on dose rates and radioiodine urinary excretion measurements for determining a proper time of discharge in radioiodine treated patients with differentiated thyroid carcinoma**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
59. **Evaluation of radioprotective effects of new synthetic amino-alkylthiocarbamic acid derivatives in mice**, 10th Congress of World Federation of Nuclear Medicine & Biology, Cape Town, South Africa, 18-23 September, 2010.
60.  **$^{99\text{mTc}}$ -MIBI redistribution in myocardial perfusion SPECT of the patients with coronary artery disease**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.
61. **Does vitamin-E decrease salivary gland damage after radioiodine therapy in patients with thyroid cancer**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.
62. **Radioprotective effects of hesperidin as a flavonoid against genotoxic effects of  $^{99\text{mTc}}$ -MIBI in human cultured lymphocytes**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.
63. **Echocardiographic functional changes in subclinical hyperthyroidism and acute hypothyroidism after L-thyroxine withdrawal in patients with thyroid cancer**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.
64. **Genotoxicity effects of  $^{99\text{mTc}}$ -MIBI in human peripheral blood lymphocytes**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.
65. **The changes of the brain perfusion pattern in schizophrenic patients in relation to symptom improvement after treatment with olanzapine**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.
66. **Gated myocardial perfusion SPECT: Effect of patient position on left ventricular functional indices**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.

67. **Value of single injection-double acquisition stress gated SPECT before and during low-dose dobutamine infusion for prediction of myocardial perfusion and function improvement after coronary artery bypass graft**, 22nd Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 10-14 October, 2009.
68. **Value of myocardial perfusion imaging for prediction of perfusion improvement after percutaneous transluminal coronary angioplasty**, SNM Annual Meeting, Toronto, Canada, 13-17 June, 2009.
69. **Effects of 111In-Oxine labeling on the survival of human mesenchymal stem cells**, 9th Asia-oceania Congress of Nuclear Medicine and Biology, New Dehli, India, 24-29 October, 2008.
70. **Iodine-131 therapy complications in mother and child in patients with differentiated thyroid carcinoma**, 21th Annual Congress of the European Association of Nuclear Medicine, Munich, Germany, 11-15 October, 2008.
71. **Radio-iodine therapy and Helicobacter pylori infection: The first in vivo evidence on radiosensitivity of the bacteria**, 21th Annual Congress of the European Association of Nuclear Medicine, Munich, Germany, 11-15 October, 2008.
72. **Synthesis and radioprotective effects of novel amino-alkyldithiocarbamic acid derivatives against  $\gamma$ -irradiation in mice**, 21th Annual Congress of the European Association of Nuclear Medicine, Munich, Germany, 11-15 October, 2008.
73. **Deviated renal axis in children with urinary tract abnormalities**, 21th Annual Congress of the European Association of Nuclear Medicine, Munich, Germany, 11-15 October, 2008.
74. **Diagnostic value of transient left ventricular dilatation for diabetic and non-diabetic patients with no significant regional myocardial perfusion abnormality**, 21th Annual Congress of the European Association of Nuclear Medicine, Munich, Germany, 11-15 October, 2008.
75. **Evaluation of radioiodine therapy in differentiated thyroid cancer (DTC) in patients with negative diagnostic I-131 whole body scans and elevated serum thyroglobulin levels: a comparison study with thallium scan**, 20th Annual Congress of the European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October, 2007.
76. **Hospital discharge policy in patients receiving iodine-131 therapy for thyroid carcinoma based on monitoring of radiation dose rate and radioiodine urinary excretion**, 20th Annual Congress of the European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October, 2007.
77. **Simple synthesis of radioiodinated N-succinimidyl-4iodobenzoate: an intermediate compound for the indirect radioiodination of antibodies**, 20th Annual Congress of the European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October, 2007.
78. **Brain perfusion abnormalities in patients with chronic symptoms studied with Technetium-99m ethyl cysteinate dimer (99mTc-ECD) more than one year**, 20th Annual Congress of the European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October, 2007.
79. **The value of 99mTc-MIBI scintigraphy for the diagnosis of multiple drug resistance in multiple myeloma patients**, 20th Annual Congress of the European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October, 2007.
80. **Angiographic findings in cardiac syndrome X comparing with myocardial perfusion imaging and exercise treadmill test**, 20th Annual Congress of the European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October, 2007.

- 81. Radioiodine treatment complications in mother and child in patients with differentiated thyroid carcinoma**, Joint Annual Scientific Meeting, Toronto, Canada, 9-13 October, 2007.
- 82. Efficacy of Radioiodine therapy in patients of differentiated thyroid cancer with elevated serum thyroglobulin and negative I-131 scan**, 2nd Conference of Asia Regional Cooperative Council of Nuclear Medicine, Ulaanbaatar, Mongolia, 3-7 September, 2007.
- 83. Mineral Density in patients with well-differentiated thyroid carcinoma**, 2nd Conference of Asia Regional Cooperative Council of Nuclear Medicine, Ulaanbaatar, Mongolia, 3-7 September, 2007.
- 84. Radioiodine therapy effects on lacrimal gland function in patients with thyroid cancer**, 2nd Conference of Asia Regional Cooperative Council of Nuclear Medicine, Ulaanbaatar, Mongolia, 3-7 September, 2007.
- 85. Assessing the diagnostic accuracy of sentinel lymph nodes lymphoscintigraphy using Tc-99m Phytate in breast cancer**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 86. Diagnostic role of Tc-99m Tetrofosmin scintigraphy in cold thyroid nodules**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 87. Changes in gonadal function in hyperthyroid patients treated with radioiodine**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 88. C-13 UBT by non dispersive isotope selected infrared (NDIR) spectroscopy vs C-14 UBT in diagnosis of HP infection**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 89. Microdose C-14 urea breath test for the diagnosis of helicobacter pylori**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 90. Discontinuing of long-term beta-blocker therapy may falsely overestimate the fixed defects in dipyridamole myocardial perfusion imaging**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 91. Comparison between three interpretative methods for diagnosis of coronary artery disease in the territory of left anterior descending artery by dipyridamole myocardial perfusion imaging in patients with left bundle branch block**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 92. Myocardial perfusion scan accuracy in detection of coronary artery disease – comparison with exercise stress test**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 93. Quantitative assessment of dacrioscintigraphic images in the evaluation of epiphora**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 94. Radiopharmaceutical regulation world wide- the resemblances and differences**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
- 95. Assessment of the Accuracy of lacrimal scintigraphy based on a prospective analysis of patients symptomatology**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.

96. **Neurospect evaluation in patients with post traumatic anosmia; a preliminary study**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
97. **Comparison between brain perfusion single photon emission computed tomography and anatomical imaging in chronic complications of traumatic head injury**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
98. **Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobuline in patients with differentiated thyroid carcinoma and negative whole body iodine scan**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
99. **Angiographic and scintigraphic features of cardiac X syndrome**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
100. **Myocardial perfusion scintigraphy role in evaluating percutaneous transluminal coronary angioplasty (PTCA) in patients with coronary artery disease**, 9th Congress of World Federation of Nuclear Medicine & Biology, Seoul, South Korea, 22-27 October, 2006.
101. **Discontinuing of long-term beta-blocker therapy may falsely overestimate the fixed defects in dipyridamole myocardial perfusion imaging**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
102. **Pre-treatment preparation of patients with differentiated thyroid carcinoma within three weeks**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
103. **99mTc-EC vs. 99mTc-MAG3: A comparative study of two radiopharmaceuticals for renal function assessment**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
104. **Radioiodine treatment effects on lacrimal gland function in patients with thyroid cancer**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
105. **Correlation of two methods of planar and SPECT scintigraphy with Tc-99m RBC in detection of liver hemangioma**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
106. **99mTc-Phytate vs. 99mTc-Sb2S3 for lymphatic mapping and gamma-guided sentinel lymph node biopsy in breast cancer: a comparative study**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
107. **Assessing the diagnostic accuracy of sentinel lymph nodes lymphoscintigraphy using 99mTc-phytate in breast cancer**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
108. **Comparison of methods for determination of glomerular filtration rate: low and high dose Tc-99m-DTPA renography, predicted creatinine clearance method and plasma sample method**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.
109. **Is there any correlation between the severity of anxiety and myocardial perfusion abnormalities detected by SPECT imaging**, 19th Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, 30 Sept-4 Oct, 2006.

- 110. On-levothyroxine measurement of thyroglobulin is not a reliable screening test for patients at high risk of remnant/recurrent differentiated thyroid carcinoma**, 8th European Congress of Endocrinology, Glasgow, UK, 1-5 April, 2006.
- 111. Efficacy of high dose radioiodine in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole body iodine scan**, 8th European Congress of Endocrinology, Glasgow, UK, 1-5 April, 2006.
- 112. Bone SPECT value for differentiating malignant from benign lesions of vertebral column in patients with known primary malignancy**, Annual Congress of the European Association of Nuclear Medicine, Istanbul, Turkey, 15-19 October, 2005.
- 113. The value of Tc-99m-MIBI scintigraphy in multiple myeloma for early detection of relapsed disease and decision for treatment**, Annual Congress of the European Association of Nuclear Medicine, Istanbul, Turkey, 15-19 October, 2005.
- 114. The value of myocardial perfusion imaging in differentiating between idiopathic dilated cardiomyopathy from the ischemic form**, Annual Congress of the European Association of Nuclear Medicine, Istanbul, Turkey, 15-19 October, 2005.
- 115. Posttraumatic anosmia: quantitative brain perfusion SPECT and clinical evaluation**, Annual Congress of the European Association of Nuclear Medicine, Istanbul, Turkey, 15-19 October, 2005.
- 116. Can rest phase study be replaced by acquisition during low-dose dobutamine infusion in ECG-gated myocardial perfusion SPECT? A novel protocol**, Annual Congress of the European Association of Nuclear Medicine, Istanbul, Turkey, 15-19 October, 2005.
- 117. Study of ablation efficiency of 3600 MBq of I-131 in the treatment of thyroid carcinoma**, International Conference on Radiopharmaceutical Therapy, Limassol, Cyprus, 11-14 October, 2005.
- 118. The rate of depression and its risk stratification in patients with differentiated thyroid cancers treated with radioactive iodine**, International Conference on Radiopharmaceutical Therapy, Limassol, Cyprus, 11-14 October, 2005.
- 119. Comparative evaluation of the two fixed dose methods of radioiodine therapy (185 MBq and 370 MBq) for the treatment of graves' disease**, International Conference on Radiopharmaceutical Therapy, Limassol, Cyprus, 11-14 October, 2005.
- 120. Bone mineral density in patients with differentiated thyroid cancer receiving suppressive dose of levothyroxine**, 52nd Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada, 18-22 June, 2005.
- 121. Effects of treatment with radioiodine (I-131) on the gonadal function of the hyperthyroid patients**, 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA, USA, 19-23 June, 2004.
- 122. Reduction of in vivo deiodination of radioiodinated of antibodies using N-succinimidyl-4-[125I]iodobenzoate**, 8th Congress of The World Federation of Nuclear Medicine and Biology, Santiago, Chile, 29 Sept - 4 Oct, 2002.
- 123. Synthesis of I-125, I-131 labelled peptides**, 4th International Conference on isotopes, Capetown, South Africa, 10-14 March, 2002.

124. **Optimization of synthesis and quality control procedures for the preparation of I-125-labelled peptides**, International Atomic Energy Agency, Final Research Co-ordinated Meeting, Shanghai, China, 30 October - 3 November, 2000.
125. **Microwave-accelerated radiohalogenation of nitroimidazole-based hypoxia markers**, Fourth International Symposium on Radiohalogens, Whistler, Canada, 9-13 September, 2000.
126. **Synthesis and radiohalogenation of 2'-IAZA, a potential analog of IAZA, as a novel radiotracer for imaging tissue hypoxia**, AFPC Conferences, Saskatoon, Canada, 24-26 June, 2000.

### National Congresses [Farsi]

1. **Novel Gd-DTPA-Peptide for targeted breast tumor magnetic resonance imaging**. Tehran, Iran, 8-9 May, 2024.
2. **Alpha-Emitting Radiopharmaceuticals: Past, Present and Future**, Tehran, Iran, 27-29 December, 2023.
3. **Quality control of radiopharmaceuticals**, Tehran, Iran, 27-29 December, 2023.
4. **Global market and pharmacoepidemiology of radiopharmaceuticals: Latest trends**
5. **and insights**, Tehran, Iran, 13-15 December, 2022.
6. **Radiopharmaceuticals market: The latest trend & analysis report of 2020**, Tehran, Iran, 12 May, 2022.
7. **Clinical application of radiopharmaceuticals**, Tehran, Iran, 15 February, 2022.
8. **Translational Nuclear Pharmacy and Radiopharmaceuticals, Future Research and Practice**, Tehran, Iran, 7 July, 2021.
9. **Preclinical studies for radiopharmaceuticals: The Iranian activities & experiences**, Tehran, Iran, 5-6 August, 2020.
10. **Computational, radiolabeling and biological studies: A diagnostic biomolecule for targeting amyloid- $\beta$  plaques in Alzheimer's disease rat model**, Tehran, Iran, 27-29 November, 2019.
11.  **$^{68}\text{Ga}$ -labeled RGD peptide as an early diagnostic agent for overexpressed  $\alpha\text{v}\beta3$  integrin receptors in Non-small cell lung cancer (NSCLC)**, Tehran, Iran, 27-29 November, 2019.
12. **Fibroblast activation protein (FAP) inhibitors: Novel ligands for PET/CT imaging**, Tehran, Iran, 27-29 November, 2019.
13. **Development of Ga-68 radiolabeled, biotinylated thiosemicarbazone dextran-coated iron oxide nanoparticles as the multimodal PET/MRI probe**. Tehran, Iran, 27-29 November, 2019.
14. **Practical flowchart for theragnostics: An experience from Shariati Hospital**, Tehran, Iran, 27-29 November, 2019.
15. **Theragnostics with Lutetium-177 labelled peptides: Changes and challenges**, Tehran, Iran, 27-29 November, 2019.
16. **Months of experience in  $^{68}\text{Ga}$ -DOTATATE PET/CT imaging in SSTR positive malignancies**, Tehran, Iran, 27-29 November, 2019.
17. **Preliminary results of treating metastatic castration-resistant prostate cancer (mCRPC) patients using Lu-177-PSMA**, Tehran, Iran, 27-29 November, 2019.
18. **Radiopharmaceuticals Market: Latest Trend & Analysis Report of 2018**, Tehran, Iran, 27-29 November, 2019.
19. **Nuclear pharmacy practice - An overview**, Tehran, Iran, 27-29 November, 2019.
20.  **$^{18}\text{F}$ -FDG Production and Quality Control: An Overview**, Yazd, Iran, 23-25 November, 2018.

21. **Radiopharmaceuticals Market: Latest Trend & Analysis Report of 2017** ,Yazd, Iran, 23-25 November, 2018.
22. **New peptide based radiopharmaceutical for melanoma imaging**, Mahmoudabad, Iran, 26-28 October, 2016.
23. **Factors interfering with myocardial 18F-FDG uptake in oncologic PET-CT imaging**, Mahmoudabad, Iran, 26-28 October, 2016.
24. **68Ga-Radiopharmaceuticals in PET Imaging: The future Perspectives**, Mahmoudabad, Iran, 26-28 October, 2016.
25. **Radiopharmaceuticals Consumption: Iran vs. Global Market Review in 2014**, Mahmoudabad, Iran, 26-28 October, 2016.
26. **Preparation and Evaluation of 68Ga-ECC as a PET Renal Imaging Agent**, 19th Iranian Congress of Nuclear Medicine, Hamedan, Iran, 16-18 September, 2015.
27. **Optimized production and quality control of 68Ga-EDTMP for small clinical trials**, 19th Iranian Congress of Nuclear Medicine, Hamedan, Iran, 16-18 September, 2015.
28. **Production of 68Ga-Ethyl cysteinate dimmer for PET studies**, 19th Iranian Congress of Nuclear Medicine, Hamedan, Iran, 16-18 September, 2015.
29. **Nuclear Medicine Market Worldwide**, 19th Iranian Congress of Nuclear Medicine, Hamedan, Iran, 16-18 September, 2015.
30. **Turkey vs. Iran – Nuclear Medicine Comparison**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
31. **Prospective management of the production and clinical applications of radiopharmaceuticals in Iran: Opportunities and challenges**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
32. **Preparation and quality control of 111In-Plerixafor for CXCR4 imaging**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
33. **Synthesis and evaluation of 67Ga-plerixafor; a novel imaging agent for targeting chemokine receptor CXCR4**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
34. **Synthesis and Evaluation of [68Ga]- plerixafor for PET imaging of human colorectal carcinoma**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
35. **Radiosynthesis and biodistribution studies of [62Zn/62Cu]– plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
36. **Radiolabeling of a melanocyte stimulating hormone derivative for single photon imaging**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
37. **Production, Radiolabeling Optimization and Imaging Studies a combined 153Sm/177Lu-EDTMP formulation as a novel potential radiopharmaceutical for metastatic bone pain palliation therapy**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
38. **One step radiolabeling of peptide LIKKPF with 18FDG for detecting of apoptosis**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.

39. **Comparison of curability of tumors treated with targeted radionuclide therapy and external beam radiotherapy**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
40. **Lower limbs perfusion scintigraphy in patients referred for myocardial perfusion imaging**, 18th Iranian Congress of Nuclear Medicine, Tehran, Iran, 12-14 November, 2014.
41. **Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer**, 14th Iranian Annual and International Congress of Nuclear Medicine, Mashhad, Iran, 4-6 November, 2010.
42. **The effectiveness of <sup>153</sup>Sm-EDTMP for palliative therapy of patients with painful multiple bone metastases**, 14th Iranian Annual and International Congress of Nuclear Medicine, Mashhad, Iran, 4-6 November, 2010.
43. **The distribution of bone metastases on 146 whole body scans**, 14th Iranian Annual and International Congress of Nuclear Medicine, Mashhad, Iran, 4-6 November, 2010.
44. **Predicting factors of successful post-surgical remnant ablation in radioiodine-treated patients with differentiated thyroid carcinoma**, 14th Iranian Annual and International Congress of Nuclear Medicine, Mashhad, Iran, 4-6 November, 2010.
45. **Development of second primary cancer in radioiodine treated patients with differentiated thyroid carcinoma**, 14th Iranian Annual and International Congress of Nuclear Medicine, Mashhad, Iran, 4-6 November, 2010.
46. **PET scanning of pediatric tumors**, 20th international congress of pediatrics, Tehran, Iran, 7-14 October, 2008.
47. **New therapeutic radiopharmaceuticals in Iran**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
48. **Preparation of patients with thyroid cancer for I-131 scintigraphy or therapy by 1-3 weeks of levothyroxine discontinuation or after total thyroidectomy**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
49. **Pitfalls of FDG-PET imaging in oncology**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
50. **Renal axis deviation in urinary tract abnormalities of children; the role of DMSA renal scintigraphy**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
51. **The role of myocardial perfusion scan in diabetic patients**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
52. **PET in gastrointestinal oncology-advantages and a few pitfalls**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
53. **Radioiodine treatment complication in mother and child in patients with differentiated thyroid carcinoma**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
54. **Cytotoxicity of <sup>111</sup>In-oxine on mesenchymal stem cells: a time dependent adverse effect**, 12th Iranian Annual Congress of Nuclear Medicine, Sari, Iran, 25-27 June, 2008.
55. **Comparison between brain perfusion single photon emission computed tomography (SPECT) and anatomical imaging in chronic complications of traumatic head injury**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.

56. **NeuroSPECT evaluation in patients with post-traumatic anosmia, a preliminary study**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
57. **Assessment of the accuracy of lacrimal scintigraphy based on a prospective analysis of patients' symptomatology**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
58. **Analysis of dacryoscintigraphic images based on a simple quantitative measure**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
59. **On-levothyroxine measurement of thyroglobulin is not a reliable screening test for patients at high risk of remnant/recurrent differentiated thyroid carcinoma**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
60. **Nuclear medicine imaging techniques in the evaluation of pharmaceutical formulations**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
61. **Accuracy of myocardial perfusion scan in detection of coronary artery disease- comparison with exercise stress test**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
62. **Discontinuing of long-term beta-blocker therapy may falsely overestimate the fixed defects in dipyridamole myocardial perfusion imaging**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
63. **The best pattern of interpretation in dipyridamole myocardial perfusion scan for diagnosis of coronary artery disease in the territory of left anterior descending artery in patients with left bundle branch block**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
64. **Evaluation of a new mono-phasic imaging protocol in comparison with conventional dual-phase study of myocardial perfusion**, 10th Iranian Annual Congress of Nuclear Medicine  
Location: Tehran, Iran, 6-7 December, 2006.
65. **The relation between helicobacter pylori infection and cardiac syndrome X; a preliminary study**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
66. **The long term effects of mustard gas on myocardial perfusion pattern of intoxicated warfare patients**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
67. **The role of scintigraphic perfusion imaging in the evaluation of patients before and after percutaneous transluminal coronary angioplasty**, 10th Iranian Annual Congress of Nuclear Medicine, Tehran, Iran, 6-7 December, 2006.
68. **Indirect radionuclide cystography in children**, 18th International Congress of Pediatrics, Tehran, Iran, 27 Oct-1 Nov, 2006.
69. **Renal cortical scintigraphy in children**, 18th International Congress of Pediatrics, Tehran, Iran, 27 Oct-1 Nov, 2006.
70. **Nuclear medicine role in neonatal jaundice**, 18th International Congress of Pediatrics, Tehran, Iran, 27 Oct-1 Nov, 2006.
71. **Application of Microdose Radiolabeled 14C-Urea for the Detection of Helicobacter Pylori Infection**, The 8th National Congress of Microbiology, Isfahan, Iran, 23-25 May, 2006.

72. **Review of the role of nuclear medicine in the management of the adrenal diseases**, 13th Asia-Oceania Congress of Endocrinology, Tehran, Iran, 10-12 May, 2006.
73. **Evaluation of congenital renal fusion anomalies with 99mTc-DMSA**, 17th International Congress of Pediatrics, Tehran, Iran, 8-13 October, 2005.
74. **The role of thyroid scan in evaluating of congenital hypothyroidism**, 17th International Congress of Pediatrics, Tehran, Iran, 8-13 October, 2005.
75. **Sedation Protocols In Pediatric Nuclear Medicine**, 17th International Congress of Pediatrics, Tehran, Iran, 8-13 October, 2005.
76. **Current concepts on the diagnostic and therapeutic use of MIBG in children**, 17th International Congress of Pediatrics, Tehran, Iran, 8-13 October, 2005.
77. **Renal dynamic scan in the pediatric urinary infections**, 17th International Congress of Pediatrics, Tehran, Iran, 8-13 October, 2005.
78. **PET and pediatric neurological disorders**, 17th International Congress of Pediatrics, Tehran, Iran, 8-13 October, 2005.
79. **Production of positron emitter radiopharmaceuticals: radiolabelling techniques**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
80. **The value of myocardial perfusion imaging in differentiating between idiopathic dilated cardiomyopathy from the ischemic form**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
81. **Evaluation of diagnostic of 99mTc-Tetrofosmin scintigraphy in cold thyroid nodules**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
82. **The effectiveness of 131I therapy in thyroglobuline positive 131I whole body scan negative patients with differentiated thyroid carcinoma**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
83. **Internal dosimetry in nuclear medicine using a thyroid mathematical model**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
84. **Health and safety aspects of nuclear medicine**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
85. **Comparative study of renal function with 99mTc-MAG3 and 99mTc-EC**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
86. **Prevalence of depression in patients with differentiated thyroid cancer treated with radioactive iodine**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
87. **Quantitative assessment of salivary glands function in thyroid cancer patients after radioiodine therapy**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
88. **90Y-Ibritumomab Tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's Lymphoma**, The 8th Annual Meeting of Nuclear Medicine, Tehran, Iran, 17-18 November, 2004.
89. **Radioisotopic cystography in diagnosis of vesicoureteral reflux**, 16th International Congress of Pediatrics, Tehran, Iran, 8-13 October, 2004.

90. **The value of  $^{99m}\text{Tc}$ -MIBI Scintigraphy in active disease and remission phase of multiple myeloma**, 4th National Iranian Congress of Hematology & Oncology and Nursing Meeting, Mashhad, Iran, 24-26 June, 2004.
91. **Leukocyte radiolabelling with  $^{99m}\text{Tc}$ -HMPAO for imaging of inflammation and infection**, The First Congress of Early Detection of Disease, Hamedan, Iran, 12-15 May, 2003.
92. **Evaluation of new drug delivery systems using gammascintigraphy”, 1st National Conference on Novel Drug Delivery Systems**, 1st National Conference on Novel Drug Delivery Systems, Tehran, Iran, 26-27 February, 2003.
93. **Synthesis of b-2-IAZA, a novel radiotracer of tissue hypoxia**, The 6th Iranian Annual Meeting of Nuclear Medicine, Mashhad, Iran, 19-21 October, 2002.
94. **A novel synthesis of  $^{125}\text{I}$ -labelled N-succinimidyl-4-idobenzoate for use in antibody labelling**, 8th Iranian Seminar of Pharmaceutical Sciences, Shiraz, Iran, 27-29 August, 2002.
95. **Synthesis of radioiodinated of N-succinimidyl-4-idobenzoate for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine**, 7th Iranian Organic Chemistry Conferences, Tehran, Iran, 12-13 September, 1999.
96. **A HPLC method for evaluation of bioavailability of generic dipyridamole tablets**, Second Iranian Seminar of Pharmacy Students, Mashhad, Iran, 21-22 October, 1995.

#### SHORT COURSES / WORKSHOPS

1. **Student Evaluation and Online Assessment**, Education Development Center, TUMS, Iran, 26 August 2020, Learner
2. **The Design and Implementation of Multiple Choice Questions (MCQs)**, Education Development Center, TUMS, Iran, 7-8 July 2020, Learner
3. **Introduction to Research Ethics**, Virtual School, TUMS, Iran, 8 March 2017, Learner
4. **OvidSP Platform**, Wolters Kluwer, Tehran, Iran, 16 November 2015, Learner
5. **Plagiarism Workshop**, Kowsar Academy, Tehran, Iran, 27 November 2014, Learner
6. **Clinical Research and Drug Safety**, Merck Serono Company, The Middle East and Near East Region, 19 December 2013, Learner
7. **Workshop for Blood and Blood Component Handling & Haemovigilance System**, Iranian Blood Transfusion Organization, 31 October 2013, Learner
8. **Basic cGMP and Quality Control of  $^{18}\text{F}$ -FDG**, Eczacibaci/Monrol Company, Turkey, 19-23 November 2012, Learner
9. **Requirements for Board Exam for Teachers**, The Ministry of Health and Medical Education, Iran, 16 August 2012, Learner
10. **Workshop for Implementation of Relative Value of Health Services**, The Ministry of Health and Medical Education, Iran, 1 February 2011, Learner
11. **Open Journal Systems (OJS) – Workshop**, Tehran University of Medical Sciences, Tehran, Iran, 16 January 2011, Learner
12. **The Methods of Standard Setting**, Tehran University of Medical Sciences, Tehran, Iran, June 2007, 13 Lecturer
13. **Knowledge Translation & Utilization of Research Results**, Tehran University of Medical Sciences, Tehran, Iran, 13 December 2006, Learner

14. **SPSS Software**, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 30-31 May 2006, Learner
15. **Exam Evaluating and Questions Preparation**, Tehran University of Medical Sciences, Tehran, Iran, 5 May 2006 , Learner
16. **Radiopharmaceuticals Quality Control**, Atomic Energy Organization of Iran , Tehran, Iran, 11-15 March 2006, Learner
17. **EndNote Software**, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 22-23 December 2005, Learner
18. **Reference Manager Software**, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 18-20 September 2005, Learner
19. **Scientific writing**, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 23 February 2005, Learner
20. **Research Methodology**, Institute of Public Health Researches, Tehran University of Medical Sciences, Tehran, Iran, 18-25 October, 2000, Learner
21. **Radiation Safety Course**, Radiation Control Committee, University of Alberta, Canada, 3-8 February 2000, Learner

## GRANTS & CONTRACTS

1. **Synthesis, quality control and biodistribution study of radiolabeled somatostatin receptor antagonist for treatment of neuroendocrine tumors expressing the somatostatin receptor (SSTR)**, Status: Completed, 2019
2. **Synthesis, quality control and biodistribution study of <sup>99m</sup>Tc-labeled hexapeptide derivative in order to molecular imaging and diagnosis of  $\beta$ -amyloid plaques in Alzheimer's disease**, Status: Completed, 2019
3. **Comparison of <sup>68</sup>Ga-DOTATATE PET/CT, <sup>99m</sup>Tc-octreoscan SPECT/CT and CT-scan/MR imaging in the detection of tumoral lesions in neuroendocrine tumors**, Status: Completed, 2019
4. **Synthesis of anti-cancerous thiosemi- and semi-Cabazon ligands, radiolabeling with Ga-67, 68 and in-vivo evaluation in animal models**, Status: Completed, 2019
5. **Preparation and optimizing recombinant complement receptor 2 to be labeled with radioisotope for ischemia reperfusion injury scintigraphy**, Status: Completed, 2018
6. **Preparation, quality control and biodistribution study of radiolabelled Bombesin nanoparticles for In Vivo Gastrin Releasing Peptide-Receptor Imaging**, Status: Completed, 2018
7. **Design, synthesis, radiolabeling and biological evaluation of a new peptide as PSMA imaging agent in prostate cancer**, Status: Completed, 2017
8. **Synthesis, radiolabeling, quality control and biological evaluation of LIKKPF peptide and its analogs with <sup>18</sup>F-FDG for in vivo imaging of apoptosis**, Status: Completed, 2017
9. **Evaluation of <sup>99m</sup>Tc-alpha MSH in the diagnosis of primary and metastatic melanoma**, Status: Completed, 2017
10. **Efficacy of adding bone-seeking radiopharmaceuticals (samarium-153 or strantium-89) on local radiation in metastatic bone involvement**, Status: Completed, 2016.
11. **Preparation, quality control and biodistribution study of radiolabelled Bombesin nanoparticles for In Vivo Gastrin Releasing Peptide-Receptor Imaging**, Status: Running, 2015.
12. **Evaluation of <sup>99m</sup>Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease and its differentiation from other types of Parkinsonism syndrome**, Status: Completed, 2015.

13. **Synthesis, quality control and biodistribution study of  $^{99m}\text{Tc}$ -labeled  $\alpha$ -MSH derivative for diagnosis of melanoma**, Status: Completed, 2014.
14. **The relationship between nephropathy in diabetes mellitus type 2 and severity and extent of myocardial ischemia and myocardial dysfunction**, Status: Completed, 2013.
15. **Evaluation of the quality of life in patients with differentiated thyroid carcinoma treated with radioiodine-131 in Dr. Sahriati hospital**, Status: Completed, 2012.
16. **Evaluation of post-thyroidectomy preablative thyroglobulin and anti-thyroglobulin level relation with radioiodine therapy response in patients with differentiated thyroid cancer**, Status: Completed, 2012.
17. **Radiolabeling, quality control and biological evaluation of non-peptide CRCR4 antagonists for targeted diagnosis and therapy of malignancies**, Status: Completed, 2012.
18. **Comparison of radiosynovectomy efficacy with Re 188 sulfur colloid and Y-90 colloid in patient with chronic inflammatory knee joint disease**, Status: Completed, 2011.
19. **The evaluation of Re-HEDP efficacy in metastatic bone pain palliation therapy**, Status: Completed, 2011.
20. **Evaluation of  $^{99m}\text{Tc}$ -bombesin in the diagnosis of breast cancer and its differentiation from benign lesions**, Status: Completed, 2011.
21. **Compensation for collimator-detector blurring for brain SPECT resolution enhancement**, Status: Completed, 2010.
22. **Salivary gland function evaluation after radioiodine therapy with doses equal or less than 100 mCi for either thyroid cancer or hyperthyroid state**, Status: Completed, 2010.
23. **Cardiac perfusion changes in patients treated for breast cancer with radiation therapy**, Status: Completed, 2010.
24. **Synthesis, quality control and biodistribution study of some  $^{99m}\text{Tc}$ -labeled substance P derivatives for diagnosis of neurokinin receptor (NKr) expressing tumors**, Status: Completed, 2010.
25. **The image quality and myocardial to visceral uptake ratio in myocardial perfusion scan using pharmacological stress with sub-maximal exercise in comparison with pharmacological stress alone**, Status: Completed, 2009.
26. **Evaluation of myocardial perfusion scintigraphy with Tc-99m sestamibi by ECG Gated SPECT method in determining one year prognosis of patients suspicious for coronary artery disease**, Status: Completed, 2009.
27. **Evaluation of abnormal findings in myocardial perfusion scan of asymptomatic diabetic patients**, Status: Completed, 2009.
28. **Evaluation of Tc-99m Ubiquidine in specific diagnosis of infection and differentiate it from noninfectious inflammations in diabetic patient's foot ulcers**, Status: Completed, 2009.
29. **Evaluation of Tc-99m Ubiquidine in specific diagnosis of infection and differentiate it from noninfectious inflammations in orthopaedic infection**, Status: Completed, 2009.
30. **Evaluation of different factors related to the patient or procedural techniques inducing reverse perfusion pattern in myocardial perfusion scan with Tc 99m MIBI**, Status: Completed, 2009.

31. Evaluation of the efficacy and complications of  $^{153}\text{Sm}$ -EDTMP in palliative therapy of multiple bone metastases, Status: Completed, 2008.
32. Evaluation of short-term efficacy of  $^{131}\text{I}$  re-treatment in patients with differentiated thyroid cancer who have undetectable stimulated serum Tg levels and positive whole body scan in thyroid bed after initial ablative therapy, Status: Completed, 2007.
33. The value of myocardial perfusion and function assessment with  $^{99\text{mTc}}$ -MIBI Gated SPECT before and after low dose dobutamine in prediction of the perfusion and function improvement after revascularization, Status: Completed, 2007.
34. Evaluation of the correlation between serum creatinine and GFR in acute renal necrosis in comparison with other causes of acute renal failure, Status: Completed, 2007.
35. Evaluation of nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma, Status: Completed, 2007.
36. Evaluation of the effect of low dose dobutamine infusion on  $^{99\text{mTc}}$ -MIBI redistribution in patients with coronary artery disease using SPECT gamma camera, Status: Completed, 2007.
37. Evaluation of protective effects of Hesperidin against genetic damage induced by  $^{99\text{mTc}}$ -MIBI in human peripheral blood lymphocytes, Status: Completed, 2007.
38. Evaluation of effectiveness of Vit E and Bethanechol for prevention of salivary gland dysfunction in thyroid cancer patients candidate for radioiodine therapy, Status: Completed, 2006.
39. Agreement of two methods of planar and SPECT scintigraphy with  $^{99\text{mTc}}$  RBC in detection of liver hemangioma, Status: Completed, 2006.
40. Evaluation of the effect of discontinuing beta-blocker drugs on dipyridamole myocardial perfusion imaging (DMPI) in patients who were on long-term beta-blocker therapy, Status: Completed, 2006.
41. Evaluation of diagnostic value of single injection-double acquisition gated SPECT imaging with low dose dobutamine-enhancement in comparison with conventional myocardial perfusion scan with  $^{99\text{mTc}}$  MIBI for diagnosis of myocardial perfusion abnormalities, Status: Completed, 2006.
42. Comparison of myocardial perfusion between chemical warfare victims and normal individuals by SPECT, Status: Completed, 2005.
43. The prevalence of increased gastric wall radiotracer uptake in Sestamibi myocardial perfusion SPECT and its association with symptoms of dyspepsia, Status: Completed, 2005.
44. Assessment of different filters for reconstruction of the images in myocardial SPECT based upon image contrast and diagnostic value of scan for diagnosis of coronary artery disease, Status: Completed, 2004.
45. Evaluation of therapeutic efficacy of treatment with olanzapine and haloperidol on regional cerebral blood flow measured by SPECT in patients with schizophrenia; correlating with the response to treatment, Status: Completed, 2004.
46. Efficacy of  $^{99\text{mTc}}$ -Phytate for pre and intraoperative sentinel lymph node detection in the breast cancer, Status: Completed, 2004.
47. Nuclear medicine cardiac SPECT and its denoising by Platelet-based Maximum Penalized Likelihood Estimation (MPLE) method, Status: Completed, 2004.

48. **Value of Tc99m-MIBI scintigraphy in the diagnosis of multiple drug resistance in multiple myeloma patients**, Status: Completed, 2004.
49. **Evaluation of diagnostic accuracy of myocardial perfusion scans with different patterns of interpretation in identification of coronary artery disease among patients with left bundle branch block**, Status: Completed, 2004.
50. **Evaluation of the diagnostic accuracy of sentinel node biopsy (SLN) in staging of breast cancer with Lymph node dissection under guiding of scintigraphic probe using 99mTc-Sb2S2**, Status: Completed, 2004.
51. **Bone SPECT value for differentiating malignant from benign lesions of vertebral column in patients with known primary malignancy**, Status: Completed, 2004.
52. **Evaluation of relative occurrence of mother and fetus complications in women with differentiated thyroid carcinoma treated with radioactive iodine**, Status: Completed, 2004.
53. **Myocardial perfusion scan role in evaluating Percutaneous Transluminal Coronary Angioplasty (PTCA) in patients with coronary artery disease**, Status: Completed, 2004.
54. **Preparation of patients with thyroid cancer for I131 scintigraphy or therapy by 1-3 weeks of levothyroxine discontinuation or after total thyroidectomy**, Status: Completed, 2003.
55. **Study of treatment of thyroid carcinoma using low 131I<1110MBq in comparison with that of routinely used high activity 131-I>3660MBq**, Status: Completed, 2003.
56. **A Comparative study between Tc-EC 99m and 99m-TcMAG3 in evaluation of renal function in patients**, Status: Completed, 2003.
57. **Evaluation of dacryoscintigraphy in the diagnosis of lacrimal apparatus obstruction**, Status: Completed, 2003.
58. **Evaluation of the diagnostic value of erythrocyte sedimentation rate (ESR) and absolute neutrophil count in detection of pyelonephritis (based on the DMSA scan findings) in children with first time urinary tract infections**, Status: Completed, 2003.
59. **Assessment of treatment requirement in patient with differentiated thyroid cancer and undetectable serum thyroglobulin and positive 131-I whole body scan only in thyroid bed**, Status: Completed, 2003.

#### **THESIS (ADVISOR/CONSULTER)**

1. **Synthesis, quality control and biodistribution study of radiolabeled somatostatin receptor antagonist for treatment of neuroendocrine tumors expressing the somatostatin receptor (SSTR)**, Hossein Behnammanesh, Ph.D, Radiopharmacy, 2019.
2. **Evaluation of FDG uptake in fatty liver in PET-CT scan and its impact on diagnostic accuracy of extrahepatic tumor assessment**, Yeganeh Rahmani, MD, Nuclear Medicine Specialty, 2019.
3. **Evaluation of troDAT-scan in differentiation of lewy body dementia and alzheimer disease**, Farzaneh Baseri, MD, Nuclear Medicine Specialty, 2019.
4. **Evaluation and comparison of 131I-MIBG and 68Ga-DOTATATE PET in patients with neuroendocrine tumors including neuroblastoma and pheochromocytoma**, Pezhman Shahrokhi, MD, Nuclear Medicine Specialty, 2019.
5. **Preparation of radiolabeled bombesin nanoparticles for in vivo gastrin-Releasing peptide receptor imaging**, Maliheh Hajiramezanali, Ph.D, Radiopharmacy, 2019.

6. **Atherogenic consequence of antiepileptic drugs: a study of myocardial perfusion with myocardial perfusion imaging**, Zeinab Paymani, MD, Nuclear Medicine Specialty, 2019.
7. **Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to conventional 99mTc-Octreotide SPECT/CT and morphologic modalities**, Reyhaneh Manafi-Farid, MD, Nuclear Medicine Specialty, 2019.
8. **Synthesis of iron oxide PAMAM dendrimer coated nanoparticles, 68Ga radiolabeling, quality control and its biodistribution in normal and fibrosarcoma bearing rats and evaluating the images by PET-CT**, Tinoosh Almasi, Ph.D, Medical Physics, 2019.
9. **Design, synthesis, radiolabeling and biological evaluation of a new peptide as PSMA imaging agent in prostate cancer**, Mona Mosayebnia, Ph.D, Radiopharmacy, 2018.
10. **The value of 99mTc- $\alpha$ -MSH in diagnosis of primary and metastatic lesions of malignant melanoma**, Rahman Etemadi, MD, Nuclear Medicine Specialty, 2018.
11. **Evaluation of relationship between 18F-FDG PET/CT findings in vertebral/hip bones and bone mineral density**, Hamidreza Amini, MD, Nuclear Medicine Specialty, 2018.
12. **Comparison of radionuclide ventriculography using SPECT and planar techniques to evaluate LVEF in breast cancer patients during treatment with Trastuzumab**, Hajar Alebooye, MD, Nuclear Medicine Specialty, 2018.
13. **Assessment of relationship between tumor markers level and FDG-PET/CT scan findings in colorectal carcinoma patients**, Ali Kafshgar, MD, Nuclear Medicine Specialty, 2017.
14. **Assessment of correlation between gastric FDG uptake and 14C-UBT results**, Fatemeh Farsyabi, MD, Nuclear Medicine Specialty, 2017
15. **Assessment of relationship between thyroglobulin and thyroglobulin antibody levels and FDG-PET/CT scan findings in differentiated thyroid cancer patients**, Hila Aghaei, MD, Nuclear Medicine Specialty, 2017
16. **Assessment of lower limbs perfusion with 99mTc-MIBI in patients with intermediate pretest probability of coronary artery disease referred for myocardial perfusion imaging**, Sanaz Katal, MD, Nuclear Medicine Specialty, 2016.
17. **Efficacy of adding bone-seeking radiopharmaceuticals (samarium-153 or strantium-89) on local radiation in metastatic bone involvement**, Saeed Davoodian, MD, Radiation Oncology Specialty, 2016.
18. **Evaluation of delayed cardiac perfusion changes in patients with breast cancer treated by radiotherapy**, Forough Kalantari, MD, Nuclear Medicine Specialty, 2016.
19. **Comparison of sensitivity and specificity of Tc-99m somatostatin analogs (octreotide) and I-131 MIBG scintigraphies in diagnosis and localization of pheochromocytoma and neuroblastoma**, Arefeh Mirzabeigi, MD, Nuclear Medicine Specialty, 2016.
20. **Evaluation of correlative factors and patterns of FDG myocardial uptake in the patient's with malignancy**, Bahar Mossess Ghafari, MD, Nuclear Medicine Specialty, 2016.
21. **Synthesis, radiolabeling, quality control and biological evaluation of LIKKPF peptide and its analogs with 18F-FDG for in vivo imaging of apoptosis**, Sepideh Khoshbakht, Ph.D, Radiopharmacy, 2016.
22. **Evaluation of post-thyroidectomy preablative thyroglobulin and anti-thyroglobulin level relation with radioiodine therapy response in patients with differentiated thyroid cancer**, Mohammad Reza Valipouri, MD, Nuclear Medicine Specialty, 2015.

23. **Novel combined agents for palliative treatment of bone pain**, Hasan Ranjbar, Ph.D, Physics-Medical Radiation, 2015.
24. **Synthesis, quality control and biodistribution study of <sup>99m</sup>Tc-labeled  $\alpha$ -MSH derivative for diagnosis of melanoma**, Danial Shamshirian, Ph.D, Radiopharmacy, 2015.
25. **Assessment of post stress stunning in diagnosis and classification of patients with suspected CAD**, Asghar Akbari, MD, Nuclear Medicine Specialty, 2015.
26. **Assessment of prognosis and prognostic factors in patients with lymph node involvement from differentiated thyroid carcinoma origin**, Mehraneh Mostafavi, MD, Nuclear Medicine Specialty, 2015.
27. **Comparative evaluation of prognosis in patients with differentiated thyroid cancer based on elevated tg (>2ng/dl) and whole body scan findings after ablative therapy**, Negar Ahmadpour, MD, Nuclear Medicine Specialty, 2015.
28. **Evaluation of prognosis and factors effective of pediatric patients (<18yr) with differentiated thyroid carcinoma**, Masoomeh Havasi, MD, Nuclear Medicine Specialty, 2015.
29. **Evaluation of <sup>99m</sup>Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease and its differentiation from other types of parkinsonism syndroms**, Atefeh Esmaeili, MD, Nuclear Medicine Specialty, 2015.
30. **Regulations and policies concerning the manufacture, preparation, importation, exportation, transportation and waste management of radiopharmaceuticals**, Hesam Alibakhshi, M.Sc, Pharmaceutical regulatory affairs/quality assurance, 2015.
31. **Radiolabeling, quality control and biological evaluation of the AMD3100 as non-peptide CXCR4 antagonist for targeted diagnosis of related human malignancies and optimization of its synthesis**, Ayuob Aghanejad, Ph.D, Radiopharmacy, 2015.
32. **Preparation and quality control of radio-labeled Porphyrin derivatives with radiolanthanides for therapeutic purposes**, Nasim Vahidfar, Ph.D, Radiopharmacy, 2014.
33. **Evaluation of relationship between nephropathy and severity/extent of cardiac ischemia in type 2 diabetic patients by myocardial perfusion scan**, Niloofar Tavakoli, MD, Nuclear Medicine Specialty, 2014.
34. **Evaluation of short-term efficacy of I-131 re-treatment in patients with differentiated thyroid cancer who have undetectable stimulated serum Tg levels and positive whole body scan in thyroid bed after initial ablative therapy**, Somayeh Sahari, MD, Nuclear Medicine Specialty, 2014.
35. **Assessment of related factors in patients with CAD and mild to severe LV dysfunction by phase analysis of gated-SPECT myocardial perfusion imaging**, Afsaneh Khorami, MD, Nuclear Medicine Specialty, 2014.
36. **Radiolabeling, quality control and biological evaluation of the AMD3100 as non-peptide CXCR4 antagonist for targeted diagnosis of related human malignancies and optimization of its synthesis**, Ayoub Aghanezhad, Ph.D, Radiopharmacy, 2014.
37. **Production of a new peptide analog of neurotensin and labeling it with <sup>99m</sup>Tc for detection of NT1 positive receptors**, Nakisa Zarrabi, Ph.D, Cell and Molecular Biology, 2013.

38. **In vitro screening of new Triazol and Oxadiazole derivatives as benzodiazepine receptor agonists, using radioligand receptor binding assays**, Fatemeh Ahmadi, Ph.D, Radiopharmacy, 2013.
39. **Evaluation of the sensitivity and normalcy rate of myocardial perfusion scan using SPECT vs. SPECT-CT for the diagnosis of ischemic heart disease**, Arman Hasanzadeh, MD, Nuclear Medicine Specialty, 2013.
40. **The evaluation of Re-HEDP efficacy in metastatic bone pain palliation therapy**, Maryam Tajik, MD, Nuclear Medicine Specialty, 2012
41. **Cardiac perfusion changes in patients treated for breast cancer with radiation therapy**, Hanieh Zamani, MD, Nuclear Medicine Specialty, 2012.
42. **Evaluation of the quality of life in patients with differentiated thyroid carcinoma treated with radioiodine-131**, Seyed Kazem Razavi, MD, Nuclear Medicine Specialty, 2012.
43. **Synthesis, quality control and biodistribution study of some 99mTc-labeled substance P derivatives for diagnosis of neurokinin receptor (NKr) expressing tumors**, Saeed Mozafari, Ph.D, Radiopharmacy, 2012.
44. **Evaluation of different factors related to the patient or procedural techniques inducing reverse perfusion pattern in myocardial perfusion scan with Tc 99m MIBI**, Yalda salehi, MD, Nuclear Medicine Specialty, 2011.
45. **Protective effects of hesperidin against genotoxicity induced by 99mTc-MIBI in human cultured lymphocyte cells**, Amirhossein Ahmadi, Pharm D, Pharmacy, 2010.
46. **Evaluation of the effect of concurrent submaximal exercise and pharmacologic stress on subdiaphragmatic activities in myocardial perfusion scan**, Farahnaz Aghahosseini, MD, Nuclear Medicine Specialty, 2010.
47. **Salivary gland function evaluation after radioiodine therapy with doses equal or less than 100 mCi for either thyroid cancer or hyperthyroid state**, Mohammad Karimi, MD, Nuclear Medicine Specialty, 2010.
48. **Evaluation of the effect of low dose dobutamine infusion on 99mTc-MIBI redistribution in patients with coronary artery disease using SPECT gamma camera**, Zhila Mohseni, Ph.D, Radiopharmacy, 2010.
49. **Comparing the diagnostic sensitivity and specificity of cardiac perfusion imaging with 99mTc-MIBI in five defined protocols**, Mahdi Haghghatafshar, MD, Nuclear Medicine Specialty, 2010.
50. **99mTc-Ubiquicidin [29–41], a promising radiopharmaceutical to differentiate orthopedic implant infections from sterile inflammation**, Gholamali Yousefi, MD, Nuclear Medicine Specialty, 2009.
51. **Evaluation of 99mTc-Ubiquicidin 29–41 scintigraphy in differentiation of bacterial infection from sterile inflammation in diabetic foot**, Mohammadreza Gharaei, MD, Nuclear Medicine Specialty, 2009.
52. **Evaluation of the efficacy and complications of 153Sm-EDTMP in palliative therapy of multiple bone metastases**, Arash Keivan, MD, Nuclear Medicine Specialty, 2009.

53. **Evaluation of effectiveness of Vit E and Bethanechol for prevention of salivary gland dysfunction in thyroid cancer patients candidate for radioiodine therapy**, Seyed Mohammad Abedi, MD, Nuclear Medicine Specialty, 2008.
54. **Evaluation of the correlation between serum creatinin and GFR in acute renal necrosis in comparison with other causes of acute renal failure**, Alireza Emami-Ardekani, MD, Nuclear Medicine Specialty, 2008.
55. **Evaluation of nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma**, Saeed Farzanefar, MD, Nuclear Medicine Specialty, 2008.
56. **The value of myocardial perfusion and function assessment with 99mTc-MIBI Gated SPECT before and after low dose dobutamine in prediction of the perfusion and function improvement after revascularization**, Morteza Bostani, MD, Nuclear Medicine Specialty, 2008.
57. **Evaluation of the clinical and laboratory findings in predicting of acute renal lesions by 99mTc-DMSA scan in children with first urinary tract infection**, Amir Gholami, MD, Nuclear Medicine Specialty, 2007.
58. **Evaluation of scintigraphic patterns of bone metastases in patients with different types of cancers**, MohammadBagher Khodaparast, MD, Medical Doctor, 2007.
59. **Evaluation of dacroscintigraphy in the diagnosis of lacrimal apparatus obstruction**, Ali Gholamrezanezhad, MD, Nuclear Medicine Specialty, 2006.
60. **Evaluation of I-131 treatment in patients with differentiated thyroid cancer who have high levels of serum Anti-Tg and normal whole body scan**, Mozghan NazarAhari, MD, Nuclear Medicine Specialty, 2006.
61. **Evaluation of patients with differentiated thyroid cancer with elevated Anti-Tg level and its correlation with serum TG level and whole body scan with I-131**, Sahar Mirpour, MD, Nuclear Medicine Specialty, 2006.
62. **Evaluation of radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma**, Mahsa Hadifar, MD, Medical Doctor, 2006.
63. **The value of sentinel lymph node biopsy detected by lymphoscintigraphy with 99mTc-phytate and Blue dye technique in predicting pathological status of axillary lymph nodes in patients with breast cancer**, Mohsen Arabi, MD, Nuclear Medicine Specialty, 2005.
64. **The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma**, Hossein Mirshekarpour, MD, Nuclear Medicine Specialty, 2004.
65. **Determination of the best time for sample collection during the 14C-urea breath test for the diagnosis of helicobacter pylori infection**, Mohammad Hossein Al-Seyed Hossein, Pharm D, Pharmacy, 2003.

## **EDITORIAL BOARD**

1. Iranian Journal of Nuclear Medicine; Managing Editor
2. Asia Oceania Journal of Nuclear Medicine and Biology; Editorial Board Member
3. DARU Journal of Pharmaceutical Sciences; Editorial Board Member
4. Journal of Nuclear Sciences, Engineering and Technology; Editorial Board Member

## **MEMBERSHIPS**

1. European Association of Nuclear Medicine
2. National Center of Excellence in Nuclear Medicine
3. National Center of Excellence in Radiopharmaceuticals
4. Cancer Research Network
5. Nuclear Medicine National Board of Examination
6. Radiopharmacy National Board of Examination
7. European Association of Nuclear Medicine
8. Iranian Society of Nuclear Medicine
9. Iranian Association of Pharmacists
10. Iranian Medical Council

## **RESEARCH INTERESTS**

1. Therapeutic Radiopharmaceuticals
2. Hospital radiopharmacy
3. Gammascintigraphy in the evaluation of pharmaceuticals dosage forms
4. Quality control in radiopharmacy
5. Synthesis of radiosensitizers and radioprotectors